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ABSTRACT 
New transgenic antibody production platforms enable cost-effective, rapid 
manufacturing of antibodies for clinical applications. Our lab is investigating a 
human monoclonal antibody, the Human Contraceptive Antibody (HCA), 
produced in Nicotiana benthamiana, as a candidate for a topical Multipurpose 
Prevention Technology offering both contraception and protection against 
sexually transmitted infections. HCA was developed from a sperm-agglutinating 
antibody isolated from plasma cells of an infertile woman. The antibody targets a 
GPI-anchored glycoprotein, CD52g, produced specifically by epithelial cells in 
the male reproductive tract (MRT). Due to its GPI anchor, the hypermobile 
  x 
protein coats sperm as they migrate through the MRT.  In this study, we tested 
HCA’s specificity and contraceptive properties under physiologically relevant 
conditions in vitro. We demonstrated that HCA quickly and potently 
agglutinates sperm in physiological conditions at concentrations >6.25 μg/mL. 
Sperm concentration, soluble CD52g found in seminal plasma/whole semen, or 
prolonged exposure to the low pH found in the vaginal tract did not affect 
agglutination time. We also determined that CD52g incorporates into other cells 
present in the MRT, including human immunodeficiency virus (HIV-1) infected 
cells (lymphocytes, macrophages) and the parasite, Trichomonas vaginalis (TV), 
and that HIV virions produced from CD52g-coated cells incorporate CD52g in 
the virus particle membrane. HCA alone did not agglutinate HIV or TV. Both 
pathogens, however, appeared to co-agglutinate with sperm when co-cultures 
were treated with HCA. The trapping of pathogens in sperm agglutinates 
resulted in decreased TV adherence to MatTek tissue and vaginal epithelial cells, 
and a modest neutralization of HIV-1 in TZM-bl assays. These data indicate that 
HCA is a promising candidate to achieve contraception and decrease the male-
to-female transmission of STI pathogens. 
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Chapter 1 - Introduction 
  Humans have long set themselves apart from the rest of the animal 
kingdom through a variety of behaviors and unique physiology; one notable 
example is reproduction. Female humans are regularly fertile throughout the 
year, and consequently, we have been actively developing ways to prevent 
conception. Evidence for contraceptive methods dates to the early BCEs ranging 
from spermicides in Egypt—where honey, sodium carbonate, and crocodile 
dung were mixed and applied intravaginally—to the regular intake of lead and 
mercury based drinks in China 1,2. These contraceptives ranged from benign but 
ineffective, to extremely dangerous; they also did not protect against sexually 
transmitted infections (STIs). In fact, there is only one contraceptive product on 
the market to date that protects from STIs: the condom 3. 
The male condom is perhaps the most well-known contraceptive method 
with early forms being documented throughout history. A version of the condom 
is mentioned in the Iliad where King Minos used a bladder of a goat to prevent 
transmission of disease as his semen contained “serpents and scorpions” that led 
to his queens’ illnesses and deaths 4. This simple story illustrates the condom’s 
significant public health value: contraception and disease protection. 
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Unsurprisingly, the condom was embraced early on by both sex workers and 
clients in brothels. Even the Italian author Giacomo Casanova recognized that, 
despite the discomfort due to the presence of the condom, it prevented the 
contraction of dangerous diseases like syphilis, which can lead to dementia, 
paralysis, and death if left untreated4,5. The condom reached its current form in 
1885 after the advent of rubber enabled its mass production4. Since then, 
materials have changed, lubricants have been added, and quality control has 
improved, but the condom’s original form has not undergone significant 
innovation6; it also remains the only reversible contraceptive product on the 
market available for males. In contrast, female-centered contraceptive products 
underwent a significant revolution in the 20th century resulting in over 10 
female-centered products by 20091,3,7. There are both on-demand and long acting 
reversible contraceptives (LARCs), many of which regulate menses hormones, 
but only the female condom, like the male condom, protects from STIs3,8. Despite 
the large number of contraceptive products available, over 40% of pregnancies 
worldwide are unplanned, and recently the global prevalence of STIs has 
increased9–12. Both trends indicate a need for a multipurpose prevention 
technology (MPT) product that offers both contraception and STI protection.  
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The Contraceptive Gap 
Public Health Context 
According to a meta-analysis, approximately 40% of pregnancies 
worldwide are unintended. The trend is reflected in countries in both the 
developing (39%) and developed (47%) world hinting at a global phenomenon 
reaching beyond resource and education disparities13. A rapidly growing 
population, concerns about climate change, and subsequent concerns about 
available environmental resources have made the need for family planning an 
even greater priority7.  According to recent United Nations World Population 
Prospects, the global population is currently 7.5 billion, and median projections 
suggest that the world could reach 10 billion by 2050, if fertility and life 
expectancy rates remain consistent14,15. Should fertility rates vary by even +0.5 
children, the population could reach 11 billion16,17. Additionally, data shows that 
214 million women of reproductive age in the developing world wishing to 
avoid pregnancy do not have access to modern forms of contraception18,19. In fact, 
recent United Nations (UN) estimates indicate that in some countries, only 60% 
of contraceptive needs are met19 (Figure 1-1). The lack of contraceptive resources 
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hampers people’s reproductive right to freely decide if and when to have 
children19. 
 
Figure 1-1- Contraceptive demand satisfied by modern methods (percentage), by region. From 
World Family Planning 2017 – Highlights, by United Nations, Department of Economic and Social 
Affairs, Population Division. ©United Nations 2017. Reprinted with the permission of the United 
Nations 
The Accessibility Gap 
Accessibility, both physical and economical, can impact the public health 
contribution of contraceptives. A lack of accessibility is currently the limitation 
with most products on the market: over half of the current contraceptives require 
a medical professional to prescribe or place the prophylactic3,10. In places were 
medical attention is scarce or where healthcare facilities that dispense 
contraceptives require extensive travel, acquiring contraception may not be an 
option10,19,20.  A study in Bangladesh found women are significantly less likely to 
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use contraceptives if they must travel for more than 30 minutes to acquire a 
product 10,21. In contrast, contraceptive accessibility, achieved by decreasing the 
cost of contraceptive and making LARCs readily available, was found to 
decrease unintended pregnancies. The CHOICE study, specifically, found a 4-
fold decrease in adolescent pregnancy rates in St. Louis, Missouri, United States 
(US)22–25 when LARCs were made directly available to this young population, 
providing evidence for the need of a low-cost, over-the-counter, contraceptive.  
The Side Effect Gap 
In places where contraceptives can be readily acquired, side effects are an 
additional barrier to contraceptive use. Most products available are hormonal 
regulators of menses—estrogen and progesterone analogs prevent the cycling of 
the follicle-stimulating hormone and the luteinizing hormone, thus preventing 
ovulation and changing the viscosity of cervical mucus preventing sperm 
passage.26 The systemic administration of hormones, while highly effective at 
preventing pregnancy (90-99.8% effective)3,27, has the potential to induce mild to 
severe side effects including headaches28,29, modified libido27, and an increased 
risk of cardiovascular problems and deep vein thrombosis30,30–32. These side 
effects are largely eliminated with a Levonorgestrel-intrauterine device (IUD) 
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that is placed in the uterus and releases hormones locally causing fewer side 
effects33. Non-hormonal options also exist but these are often less effective, such 
as the use of diaphragms and fertility-awareness based methods, or require 
medical placement, such as copper IUDs or implant placement34. The increased 
use of Levonorgestrel-IUDs in places where it is available is demonstrative of the 
need for a non-systemic, reversible, contraceptive. 
The Discretion Gap 
A final barrier to the use of contraceptives is discretion10. Some 
contraceptives are not readily accepted worldwide or their use may have stigma 
attached. A partner’s input or permission may be required to use contraceptives 
and teenagers may require parental approval limiting access in a sexually active 
population10,19,20,35–37. The lack of discretion is the greatest limitation of the male 
and female condom.  The condom is part of basic family planning programs due 
to wide availability, accessibility, and ease-of-use9,38,39. As an on-demand barrier 
method, it has no side effects. Nonetheless, its use requires both partners’ 
consent, and it is often avoided due to reported decreased pleasure during 
coitus6,35,40,41.  Despite the lack of discretion, it is the only prophylactic that 
provides protection against both unplanned pregnancy and STIs. Consequently, 
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there is market demand for an additional easy-to-use, accessible, cost-effective, 
discreet, non-barrier contraceptive that also protects from STIs. 
The Microbicide Gap 
The condom is a physical barrier that does not permit passage of sperm or 
STI pathogens into the male or female reproductive tract. In addition to physical 
hindrance, STI transmission can also be curbed through the use of microbicides. 
Microbicides are small molecules or biologics that when applied in the vagina or 
rectum can prevent the transmission of disease by killing or neutralizing 
infectious pathogens. Currently, there are no effective microbicides on the 
market, but their absence on shelves is not due to a lack of research.  
Lessons from Previous Microbicide Development 
The year 1992 signaled the start of determined research for safe and 
effective microbicides targeting the human immunodeficiency virus (HIV), 
gonorrhea, and chlamydia. Several microbicide research groups such as the 
International Working Group on Microbicides and the International Partnership 
for Microbicides were formed, and various new compounds were tested (Table 
1-1).  
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Table 1-1-Microbicide compounds tested in clinical trials42–49 
Microbicide 
Compound 
Agent 
Classificatio
n 
Pathogen 
Target 
Phase III 
clinical trials 
Result 
Nonoxynol-9 Surfactant HIV-1 
Chlamydia 
Yes Failed 
Pro2000 Polyanion Broad Yes Failed 
Ushercell Polyanion HIV-1 Yes Failed 
BufferGel Acidifier Broad Yes Failed 
Carraguard Polyanion HIV-1 
HPV 
Yes 
Yes 
Failed 
(62% 
protection) 
Lactobacillus 
suppositories 
Acidifier/biol
ogic 
HIV-1 No 63% 
protection in 
macaques 
Amphora/ 
Acidform 
Acidifier Neisseria 
gonorrhoeae 
HSV 
Yes but for 
contraception 
Protection in 
animal 
models 
SAVVY 
(C31G) 
Surfactant HIV-1 Yes Failed 
CAPRISA/ 
VOICE 
Antiretrovira
l (Tenofovir 
and Truvada) 
HIV-1 Yes Failed due to 
poor 
adherence 
RING/ASPIRE Antiretrovial 
(Dapivirine) 
HIV-1 Yes Protected up 
to 61% in 
women 
 
Microbicide development has focused on either mimicking/strengthening 
the FRT’s natural immune defense, inhibiting pathogen interaction with its target 
cell, or directly affecting pathogen viability and reproduction 43,45,49,50. BufferGel, 
Acidform (amphora), and Lactobacillus suppositories, were intended to maintain 
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the vaginal tract’s protective low pH43,49,51–53.  Moench, et al (2005) demonstrated 
that BufferGel at a pH 4.0-4.5 decreased HIV-1 infected PBMCs viability to 4% in 
less than 10 minutes in vitro, even in pH-neutralizing seminal plasma52. 
Unfortunately, while both BufferGel and Acidform passed Phase I and II safety 
trials54, they were not found to significantly prevent STI transmission in Phase III 
trials. Similarly, polyanion microbicides, such as Pro2000, were found to interact 
with positively charged surface proteins on pathogens and cells disrupting 
electrostatic interactions. HIV-1’s envelope protein, gp120 has a positively 
charged variable loop (V3) responsible for binding to the CD4 receptor on its 
target cell, the first step in the virus’ replication cycle55,56.  In vitro, Pro2000 
successfully disrupted V3-CD4 interaction, and subsequently protected 
macaques infected intravaginally with simian-HIV (SHIV; SIV expressing HIV-1 
envelope)57,58. But, Phase III trials were unsuccessful; SHIV relies on CXCR4 as 
co-receptor to establish infection, and most in vitro and pre-clinical trials with 
Pro2000 used R4-tropic virus. Sexually transmitted HIV-1 isolates which have a 
negatively charged or neutral V3 loop59, are predominately R5-tropic viruses 
requiring CCR5 as the co-receptor,. While Phase III clinical trials were 
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unsuccessful, Pro2000 highlighted the importance of mimicking physiologically 
relevant conditions in microbicide development58. 
Nonoxynol-9 (N-9), a well-known surfactant and spermicide, was one of 
the first broad-spectrum microbicide tested for targeting HIV-1, chlamydia, 
Trichomonas vaginalis, and gonorrhea49,60. N-9 disrupts the plasma membrane of 
cells. In the case of sperm cells, it leads to their immobilization and death. 
Similarly, N-9 disaggregates the envelope of HIV-1 and other pathogens with 
phospholipid membranes rendering the organisms neutralized46,61. In vitro, N-9 
achieved HIV-1 neutralization at concentrations of 1-10 µg/mL49. Furthermore, 
when the microbicide was tested on macaques infected intravaginally with 
Simian Immunodeficiency Virus (SIVmac)62 or chlamydia62, N-9 successfully 
prevented infection. In stark contrast, N-9’s failure in Phase III clinical trials 
found an increased transmission of STI transmission, including HIV-1 and 
gonorrhea60,63 due to N-9s cytotoxicity46,60,63. The surfactant led to the formation of 
ulcers and the disruption of epithelial cell integrity, the vagina’s primary form of 
protection, with repeated use 61,64,65. Various other broad-spectrum microbicides 
have followed suit, failing in Phase III clinical trials mostly due to a lack of 
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efficacy. In recent years, microbicide research has resurfaced, with a particular 
focus on HIV-1.  
Current Microbicide Development 
Microbicide research has recently focused on the use of antiretrovirals 
(ARVs) to prevent sexual transmission of HIV-1, specifically male-to-female 
sexual transmission. ARVs prevent retroviruses from replicating by targeting key 
steps in the viral replication cycle55, and the term is primarily used to describe 
anti-HIV-1 drugs. The recent CAPRISA/VOICE and RING/ASPIRE studies 
described below have used HIV-1-specific ARVs as microbicides, administered 
with distinct delivery systems, but have had limited success. 
The CAPRISA 004 Phase IIb clinical trial tested the efficacy of 1% 
Tenofovir gel, administered intravaginally, in preventing sexual transmission of 
HIV-1.  Tenofovir (TDF) is a nucleotide reverse transcriptase inhibitor (NRTI). 
While the study found a decrease to up to 54% in HIV-1 acquisition in trial 
participants, this level of protection was only found in women with high levels of 
adherence47,66.  Similar results were found in the VOICE trial, which had over 
5000 participants in three African countries, and compared the protection offered 
by daily oral use of antiretrovirals TDF and Truvada (a combination of 
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Emtricitabine (FTC) and TDF), and 1% TDF gel. No significant difference in 
protection was found between treatment groups and the placebo group due to 
the participants’ low adherence to the products67. In contrast, the Partners Pre-
Exposure Prophylaxis (PrEP) study—which enrolled serodiscordant heterosexual 
couples from Kenya and Uganda and investigated the prophylactic use of once-
daily TDF and TDF–FTC in preventing the transmission of HIV-1, found a 67-
75% decrease of HIV-1 incidence in participants with high adherence in both 
TDF and Truvada groups68. Additionally, there was little evidence for 
developing therapeutic resistance with daily use of these ARVs47,67–69. Altogether, 
these early ARV trials provided valuable evidence for the use of ARVs as 
microbicides, and also brought to light the importance of product acceptability 
and adherence in microbicide development.  
The RING and ASPIRE trials emphasized the need for product 
acceptability suggesting that effective microbicides must have similar criteria to 
contraceptives: they must be accessible, discreet, and convenient for consistent 
use70,71.  The RING and ASPIRE are “sister” trials that tested the microbicide 
efficacy of Dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), 
when administered with a silicone intravaginal ring (IVR)72–74.  While adherence 
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in the ASPIRE trial was inconsistent, there was a 56% increase in protection to 
HIV acquisition in groups with high adherence. Altogether, the CAPRISA and 
RING/ASPIRE trials suggest that intravaginally administered, topically applied 
Dapivirine offered microbicide protection against HIV-1 with strict adherence. 
These results are reflected in the subsequent HOPE and DREAM studies in 
which trial participants were permitted to choose their microbicide product. 95% 
of women in the DREAM study opted for the IVR,  and mathematical modeling 
(due to a lack of an adequate placebo group in these open extension studies) 
suggest HIV-1 incidence was reduced by 63% in this group75,76. The IVR is both 
discreet and convenient to use and, as study participants in the RING and 
ASPIRE studies inserted their own ring, is accessible without a medical 
professional. 
Overall, these Phase II and III trials provide evidence that topical use of 
ARV drugs can prevent sexual transmission of HIV-1; nevertheless, the need for 
more broad spectrum microbicides has become pressing as STIs are globally on 
the rise with more than 1 million new infections occurring each day worldwide77. 
A renewed interest in microbicidal research is also pressing as global incidence 
of antibiotic resistance increases, limiting treatment options78–81. An ideal 
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microbicide would therefore be accessible, discreet, designed for easy adherence 
and effective against multiple pathogens. 
 
Vaginal Histology and Immunity 
The female reproductive tract (FRT) is a mucosal tissue with complex 
histological structures, and a strong reliance on both innate and adaptive 
immunity. The lower FRT, consisting of the vagina and ectocervix (Figure 1-2), 
must balance protection against pathogens with the safe passage of sperm, and 
maintenance of commensal microbiota- which are crucial to FRT immunity and 
health82–84. The primary form of protection in the lower FRT is the formidable 
epithelial barrier consisting of a thick stratified squamous epithelial layer 
approximately 25 cells thick (150-200 μm)83,85. The epithelium is also known to be 
immunologically active, expressing varying levels of extracellular toll-like 
receptor (TLR)s 1-6, and intracellular TLR-9 that recognize pathogen associated 
molecular patterns (PAMPs) on bacteria, protozoa, fungi, and viruses86,87. In 
response to pathogen recognition by these TLRs, the cells secrete pro-
inflammatory cytokines, such as anti-viral interferons, chemokines, such as 
MCP-1, and anti-microbial peptides (AMPs)88. AMPs are particularly prevalent in 
the lower FRT and consist of defensins, cathelicidins, protease inhibitors, 
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lysozymes, and lactoferrin, all of which inhibit or neutralize pathogens. AMPs 
are stored in lamellar bodies and secreted by metabolically active epithelial cells 
in response to PAMP recognition85. AMPs are particularly concentrated on the 
apical layer of the vaginal epithelium: the stratum corneum.  
While the basal layer of the vaginal epithelium is metabolically active with 
tight junctions contributing to the integrity of the stratified barrier85,88, as the 
epithelial cells move towards the vaginal lumen they differentiate into the 
stratum cornea (Figure 1-3). Epithelial cell differentiation and cornification 
results in the extrusion of the epithelial cells’ nuclei and organelles and increases 
glycogen stores in the cells85,89,90. The cornification of the epithelial layer also 
leads to a loss of tight junctions, permitting the passage of small molecules82, and 
protecting the tissue from abrasion during intercourse82. The loosely joined 
cornified cells are a double-edged sword and could enable the penetration of 
small pathogens. As a result, in addition to the AMP stores in the stratum 
corneum and the TLRs found in the basal epithelium, mucins (and the resulting 
mucus) contribute another layer of protection to the epithelial barrier. Mucins are 
O-linked glycoproteins that are secreted or associated with the plasma 
membrane of epithelial cells in the vaginal tract and other mucosal tissues91,92. 
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They interact with antibodies and trap pathogens and immunocomplexes while 
also contributing to lubrication and pH buffering of tissue91–94. Finally, the 
glycogen stored in the stratum corneum supports a final component in the 
vaginal tissue’s immune protection: the microbiota. The vaginal microbiota, 
usually dominated by Lactobacillus sp95, produce lactic acid (LA) lowering the 
vaginal pH to ~3.5 pH96–98. Both the low pH, as shown with the BufferGel in vitro 
studies52, and the lactic acid itself are shown to have virucidal and microbicidal 
effects99. Additionally, the same bacteria produce hydrogen peroxide as a 
metabolite at concentrations shown to neutralize viral and bacterial pathogens in 
vivo, providing an additional line of defense83,100. Microbiota dysbiosis, similarly, 
has been correlated with decreased epithelial integrity and increased infection of 
sexually transmitted pathogens95,101.  
The epithelial barrier, mucosal layer, and microbiota efficiently protect the 
FRT from pathogen penetration, however, cells also play a crucial function in 
immune protection. In the lower FRT, innate immune cells predominate. Natural 
Killer (NK) cells, γδ T cells, neutrophils, dendritic cells (DCs), macrophages, and 
Langerhans cells line the basal layer of the epithelium and the lamina 
propia82,88,102. Antigen presenting cells (APCs), such as dendritic cells and 
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macrophages, actively play a role in pathogen detection since their projections 
extend into the vaginal lumen and sample the vaginal microenvironment103–105. 
While adaptive immune cells are scarcer in the FRT, T cells are found in the 
lamina propria of the vaginal tract with CD4+ T cells, B cells/plasma cells, and 
secreted antibodies contributing to immune protection closer to the 
ectocervix102,106.  
 
Figure 1-2-Schematic of female reproductive tract histology and immunology. Adapted from 
Ngyuen, (2014). Nature with BioRender 
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Figure 1-3-Vagina epithelium histology. Hematoxylin and eosin staining of vaginal tissue. 
Adapted from Anderson, 2014.  
 
The upper reproductive tract consists of the fallopian tubes, uterus, 
endometrium and endocervix (Figure 1-2), whose primary function is to facilitate 
the passage of sperm cells and maintain a semiallogeneic fetus, while also 
protecting against infection. The upper FRT consists of a monolayer of columnar 
epithelial cells relying heavily on intracellular adherence molecules, tight 
junctions, and desmosomes to maintain tissue integrity and prevent the 
unregulated passage or penetration of small molecules and pathogens from the 
lumen107. The endocervix, additionally, is known to have a ciliated epithelium 
known to mechanically carry cervical mucus towards the ectocervix and vaginal 
lumen. The endocervix, like the lower FRT actively secretes mucins, and studies 
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have found a higher concentration and diversity of mucins in the endocervix 
compared to those found in the vaginal tract (Mucins 1-6 vs Mucins 1 and 4 in 
the vagina). Reflecting the dichotomy of the upper FRT function, the mucins and 
mucus not only prevent the continued advance of pathogens from the lower FRT, 
but also play a crucial role in facilitating the passage of sperm into the 
uterus91,92,108109.  
Both innate and adaptive immune cells line the lamina propria of the 
upper FRT and Table 1-2 summarizes their distribution.  However, the extensive 
nuance in both the protection and immunotolerance mediated by these immune 
cells is beyond the scope of this dissertation. As a brief overview: IgG and IgA 
secreting plasma cells in the endocervix are responsible for antibody production 
in the FRT82,88,102,110. The mechanotransduction of mucus from the cervix also 
serves to move antibody to the lower FRT102 contributing to pathogen protection 
in the vagina, as do the macrophages and neutrophils present throughout the 
FRT. NK cells, in contrast, found in both the endocervix and endometrium 
illustrate the diverse functionality of immune cells; while NK cells are 
responsible for antibody dependent cell cytotoxicity along the FRT, they also 
mediate implantation and tolerance of the semi-allograft fetus in the 
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endometrium82,111. Finally, lymphoid aggregates, composed of T cells and B cells 
surrounded by macrophages, are characteristic of the uterine endometrium, and 
are not found anywhere else in the FRT. Their size and cell composition, much 
like the endometrial lining, varies according to the menses cycle, highlighting, 
the role hormones play in the FRT immune system, thoroughly discussed in Wira 
et al, (2015) and Taneja, (2018)102,110,112,113. 
The upper and lower tract are connected by the transformation zone (TZ) 
where the stratified squamous epithelium of the ectocervix transitions to the 
columnar epithelial monolayer of the upper FRT. The TZ, consequently, is 
particularly vulnerable to pathogens, with Draper et al. (1980), using scanning 
electron microscopy to show that Neisseria gonorrhoeae preferentially attached to 
the TZ compared to the stratified squamous epithelium or endocervical 
epithelium114. While mucins and antibodies continue to offer luminal protection 
in the TZ, the thick epithelial barrier characteristic of the lower FRT is absent115. 
This is accompanied by an increased population of adaptive immune cells 
including CD8+ T cells and CD4+ cells. While these lymphocytes provide an 
additional immunological barrier, CD4+T cells are target cells for HIV-1. 
Transcytosis of virus particles has been shown in monolayers of columnar 
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endometrial epithelial cells. Gupta et al (2013) demonstrated that HIV-1 specific 
IgG antibody increased the transcytosis of infectious virions across the epithelial 
barrier at neutral or low pH116. Transcytosis at the TZ and the increased 
prevalence and close proximity of CD4+ cells in the area make this tissue 
particularly vulnerable to the sexual transmission of HIV-1106,117. 
Table 1-2- Immune cells in FRT tissues106,118–120 
Upper reproductive tract 
Tissue Immune cells 
Fallopian tube granulocytes, NK cells, macrophages, B cells, T cells 
Endometrium granulocytes, mast cells, NK cells, macrophages, B cells, 
T cells 
Endocervix granulocytes, NK cells, macrophages, B cells, T cells 
Upper reproductive tract 
Ectocervix granulocytes, NK cells, macrophages, dendritic cells, B 
cells, T cells 
Vagina granulocytes, NK cells, macrophages, B cells, T cells 
 
Sexually Transmitted Pathogens 
Global Health Statistics 
Sexually transmitted diseases have been on the rise in recent years 
prompting global concern. There are more than 30 different pathogens known to 
be sexually transmitted worldwide including bacteria, viruses, and 
parasites/protozoa. The eight most prevalent have been grouped into four 
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“curable” infectious pathogens: Treponema pallidum (Syphilis), Neisseria 
gonorrhoeae (Gonorrhea), Chlamydia trachomatis (Chlamydia), and Trichomonas 
vaginalis; and four “incurable” viral pathogens:  herpes simplex virus (HSV), 
human papillomavirus (HPV), hepatitis B virus (HepB), and the human 
immunodeficiency virus (HIV)77,121. Pathogens considered “curable” can be 
cleared from the male and female reproductive tract with the help of antibiotics; 
although gonorrhea has recently made public health headlines due to the 
increased prevalence of antibiotic resistant strains79,122. Altogether, the WHO 
estimated in 2016 that over 376 million people were infected with one of these 
four treatable pathogens (Table 1-3)77,121. In contrast, while antiviral therapies 
exist for the four most prevalent viruses listed in Table 1-3, they are not curative. 
Rather than facilitate pathogen clearance, treatment for these viruses controls the 
progression and manages the morbidity of chronic infection.  Approximately 1.2 
billion people are estimated to be infected with at least one of these prevalent 
viral pathogens77,121. The rate of infection and the high global prevalence of these 
pathogens indicate the need for prophylactics to curb the spread of disease, 
especially for those without cure.  Preventing infection is preferable to treatment: 
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these STIs can be asymptomatic resulting in chronic infection and morbidity, or 
access to treatment could be limited for some populations 121,123.  
 Table 1-3-Most prevalent sexually transmitted pathogens77,121,124 
*Demonstrated antibiotic resistance 
NRTI=nucleoside reverse transcriptase inhibitor/ INSTI=integrase strand transfer 
inhibitor/NNRTI=non-nucleoside reverse transcriptase inhibitors/PI=protease inhibitors 
 
 
STI Epidemiology and Impact 
STIs disproportionately affect certain populations.  Women are generally 
more susceptible to acquiring STIs than their male counterparts (Figure 1-4A)39. 
Despite the robust immune response mounted by the FRT, it is often not enough 
Pathogen Prophylactic/Treatment Global Burden 
Curable/non-viral 
STIs 
Responsible for 376 million infections per year 
*Trichomonas vaginalis Metronidazole/Tinidazole 156 million cases 
Treponema pallidum Penicillin 6.3 million cases 
*Neisseria gonorrhoeae Cetriaxone/Azithromycin/ 
Doxycycline 
87 million cases 
Chlamydia trachomatis Azithromycin/Doxycycline 127 million cases 
Incurable/non-viral 
STIs 
~1.2 billion people infected 
Hepatitis B Vaccine available 240 million 
infected 
Herpes Simplex Virus Acyclovir/Famciclovir/ 
Valacyclovir 
500 million 
infected 
HIV NRTI/INSTI/NNRTI/PI 36.9 million 
infected 
Human 
papillomavirus 
Vaccine available 290 million 
infected 
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to clear STIs and reinfection is not uncommon125–127. Furthermore, STIs can be 
asymptomatic: approximately 70% of women with chlamydia and trichomoniasis 
are unaware they are infected. Asymptomatic chronic infections in females can 
cause pelvic inflammatory disease, pre-term delivery, and infertility. If STIs 
remain undetected during pregnancy, the infection can be passed on to infants 
during parturition77,121,128. STIs are also more prevalent among certain minority, 
racial, and ethnic groups in the US (Figure 1-4B)39. The CDC tracks three STIs at a 
national level and federally require notification of new cases: chlamydia, 
syphilis, and gonorrhea. Recent CDC data have indicated that the rate of 
infection of all three of these STIs is on the rise (Table 1-4) with a record breaking 
2.3 million new cases occurring in 201812,129,130.  The rise of STIs is a public health 
concern because of the increased incidence of antibiotic resistance and the 
morbidity that accompanies infection.  
Table 1-4- Rates of rising cases of CDC reportable STIs 
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Figure 1-4- USA populations susceptible to STIs. A) Rates of sexually transmitted infections in 
male and women populations from 2010 and 2016. B) Rates of STI infections amongst different 
races and ethnicity in the United States. Figures adapted from The Kaiser Family Foundation 
Report: Payment and Coverage for the Prevention of Sexually Transmitted Infections (STIs). Licensed 
under the Creative Commons License. 
The widespread prevalence of STIs and the consequent morbidity has 
severe economic impact. Disability-adjusted life-years (DALY) are used to 
measure the health impact of diseases and chronic infection by quantifying the 
loss of health due to the disease. DALYs include years of life lost and years of life 
lived with disease-related disability/morbidity.  According to recent data, the 
eight most prevalent STIs (not including HIV-1) are accountable for 12 million 
DALYs worldwide, or 12 million healthy years of life lost123. The exact financial 
burden globally is unknown, and the most recent estimates of direct cost come 
from the US.  The meta-analysis indicated that the 19.7 million cases of STIs 
reported in 2008 resulted in $11.0-20.6 billion of total medical costs, adjusted to 
the 2010 dollar131. Costs associated with sexually transmitted HIV-1 was 
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responsible for the highest percentage of economic burden (81%). This, and other 
public health studies, suggest that the life-time medical costs and DALYs of STIs 
are a greater financial public health burden than programs and products 
contributing to STI prevention would cost25,121,132,133. 
In addition to the breadth of people affected and the financial public 
health costs, STIs are problematic due to the difficulty in diagnosing them, 
treating them, and the continuous discovery of more sexually transmitted 
pathogens. The CDC and the WHO both report that most STIs cases are 
undiagnosed or undetected, especially in low and middle income countries 
(LMICs)77,121. The low-level of reporting can be due to a lack of screening; stigma, 
shyness, or concerns about sexual health24,70,134; or the asymptomatic nature of 
some of the most prevalent STIs. Furthermore, the recent epidemics of Zika (ZV) 
and Ebola virus (EV) revealed that  these viruses could be sexually transmitted, 
and that virions could be found in the MRT for outwards of 2 years post-
infection resolution135–137. The emergence or re-emergence of STIs is not limited to 
viruses. Mycoplasma genitalium, like Trichomonas vaginalis, was considered a 
minor pathogen. Now, however, Mycoplasma genitalium’s antibiotic resistance is 
rising and evidence for its role in infertility, urethritis, adverse birth outcomes 
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and increased STI/HIV-1 susceptibility in women has become apparent122,138–140. 
As previously mentioned, the emergence of antibiotic resistant strains of 
gonorrhea has also increased the urgency to develop prophylactic options for 
STIs 79,80,122. In the US, the percentage of gonorrheal isolates with elevated 
microbial minimal inhibitory concentrations (MIC) has increased from 2.5% to 
4.4%, with strains completely unresponsive to antibiotics reported in the UK and 
eastern Europe80,141. Equally problematic is a lack of treatment altogether for 
other pathogens. Many STIs are able to be self-resolved in the FRT or treated 
with antibiotics, but others remain unpreventable or incurable. Additionally, the 
presence of one STI increases the likelihood of contracting another: Syphilis, 
HSV, Trichomonas, and gonorrhea have all been reported to increase the risk of  
HIV-1 infection 2-3 fold127,139,142,143. Interestingly, attempts at targeting these 
curable STIs and decreasing their prevalence in communities at high risk of HIV 
infection did not decrease the incidence of HIV-1 transmission77,144,145. Between 
on-going emergence of STI pathogens and limited resources in their screening, 
diagnosis, and treatment, there is clearly an urgent need for a product to prevent 
STI transmission. 
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Factors Complicating the Development of Prophylactics for STI Prevention 
As previously mentioned, the FRT is a formidable mucosal tissue. The 
FRT’s epithelium forms a physical barrier preventing the penetration of 
pathogens; epithelial mucin production encourages pathogen trapping; 
cytokines, chemokine, and antimicrobial peptide production contributes to 
pathogen neutralization; and healthy microbiota symbiotically play a role in the 
FRT’s immune defense84,102,146,147.  Antibodies—whether by neutralization, 
trapping, or effector functions such as ADCC—prevent infection in hosts that 
have been previously exposed to a pathogen’s antigens through sexual 
transmission or vaccination148,149.  Finally, immune cells, including DCs, 
macrophages, PMNs, NK and T cells, can be found  interspersed in the 
epithelium and lamina propria (Figure 1-2) contributing to surveillance, 
phagocytosis, and elimination of pathogens through adaptive immunity82,106.  
        The immunology of the FRT also remains under investigation. The ability of 
the FRT to simultaneously sustain an environment that protects symbiotic 
microbiota, permit the passage of sperm and implantation of a semi-allogenic 
fetus, while actively defending the body from pathogens is not thoroughly 
understood. The changing FRT environment during puberty, menses, coitus, 
  
29 
pregnancy, and menopause increases the complexity of FRT immunology and 
prophylactic development. For instance, estradiol has been shown to augment 
the expression of polymeric immunoglobulin receptors (pIgR) responsible for the 
transport of secretory IgA across the epithelium in the uterus but decreases 
expression in lower FRT epithelium149,150. Similarly, the secretory stage of menses 
is considered the most vulnerable period of STI transmission as adaptive and 
innate immune response are negatively regulated in the FRT to increase the 
possibility of implantation113. These hormonally dictated immune response can 
decrease the success of preventative therapies such as vaccines113,148.  
Finally, vaginal microbiota also plays an active role in protecting the FRT 
against infections and complicates prophylactic development.  Lactobacillus sp., a 
common vaginal microorganism, produces lactic acid which creates an acidic 
environment hostile to many STI pathogens100.  In contrast, anaerobic vaginal 
organisms such as Prevotella sp. and Sneathia sp., can induce vaginal inflammation 
directly (through the secretion of lipopolysaccharides (LPS), for example) or by 
outcompeting commensal microbiota and depleting their protective functions 
(such as hydrogen peroxide production)151. The secretion of proinflammatory 
cytokines (such as TNF-α) in response to microbiota dysbiosis, and the resulting 
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vaginal inflammation, decrease vaginal tissue integrity and increase the risk of 
STI infection, such as HIV-1152–155. Additionally, Gardnerella vaginalis another 
anaerobic species associated with decreased vaginal health, was shown to 
metabolize and inactivate the antiretroviral agent Tenofovir when it was 
administered as a vaginal microbicide in the CAPRISA trial156. All these factors 
must also be taken into account for both vaccine development and topical 
microbicides in human FRT. 
Current Approaches to STI prevention 
There have been intense efforts focused on curbing the spread of STIs. The 
most widespread method is the modification of behavior. The use of the 
condom—the only product on the market that offers on-demand protection for 
STIs—has been prevalently featured in sexual health classes and public health 
policies, especially in the fight against the sexual transmission of HIV-16,36,157,158. 
Additional behavior-based practices include regular STI screening, (allowing for 
the early detection and treatment of disease) or modification of treatment 
guidelines; for instance, beginning treatment with stronger antibiotics to prevent 
antibiotic resistance141,159–161.  These practices, while effective if strictly adhered to, 
are often not followed precisely enough across populations to decrease the 
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incidence of STIs. As a result, research has been focused on developing products 
that can be used to prevent infection. Vaccines are the most evident, cost-
effective form of preventing the transmission of disease162–164.  
Vaccines are usually comprised of inactivated or non-infectious antigens 
that elicit a primary adaptive immune response. Vaccines induce the priming, 
activation, antigen-tailoring response and memory development of effector cells 
(T cells or B cells) that enable a faster and stronger immunological response upon 
infection or re-infection165–167. A 2015 study modelling the efficacy of different 
vaccines in China predicted that even a modest vaccine offering 50% protection 
with only 30% coverage in the Sichuan province alone could prevent 22,000 new 
infections between 2020 and 2030168. Vaccines currently exist only for two STI 
pathogens, HepB and HPV. The efficacy of the HPV vaccine in women in the US 
decreased the incidence of the most common HPV morbidity, cervical cancer,  
from 55% to 33% 133,169. The data also evidence  herd immunity contributing to the 
decreased rates of cervical cancer even in unvaccinated demographics169. 
Similarly, another study found that within four years of introduction into regular 
vaccine schedules for females between the ages of 11-12, a 56% decline in HPV 
prevalence was found133. 
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The success of the HepB and HPV vaccines has encouraged on-going 
research to develop vaccines against other prevalent STI pathogens. A hurdle in 
development, nonetheless is that correlates of protection—biomarkers that 
measure the host’s response to vaccination and predict efficacy—are not 
necessarily defined for all infectious agents170,170.  The development of a 
Chlamydia vaccine has advanced in recent years due to the discovery of novel 
nanocarrier adjuvants. Early Chlamydia vaccines, with inactivated pathogen, 
surprisingly, were found to increase infection and exacerbate symptoms. 
Research done by Stary et al, (2015) in a murine model found that exacerbated 
infection was most likely due to a wave of regulatory T cells instead of the IFN-
producing CD4+ cells needed for protection. Stary et al (2015) also found that 
mucosal vaccination (intrauterine) using the nanocarrier adjuvant was necessary 
to effectively induce the effector and resident memory T cells required to protect 
mice upon Chlamydia reinfection166. In contrast, systemic vaccination only 
provided partial protection or worsened infection162,166,171,172. Vaccines for STI 
pathogens HIV-1 and Trichomonas vaginalis are also under investigation. The 
APPROACH clinical trial is one of the latest HIV-1 vaccine trials using a mosaic 
Ad26/Ad26 and gp140 HIV-1 vaccine. Initial results, released in 2018, showed 
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67% protection in macaques challenged vaginally with SHIVmac, the highest 
protection level in a vaccine trial to date163. For Trichomonas vaginalis, vaccines 
have been developed for Trichomonas strains that infect bovine and murine 
models; however, these vaccines do not translate to the Trichomonas species that 
infect humans173. While advances for STI vaccines are evidently being made, 
progress is comparatively slow and an alternative approach is desperately 
needed. Topically applied microbicides promise to fill this product void and 
contribute to curbing STI transmission44,45,51,65,174,175. 
Topically applied microbicides neutralize or kill pathogens in the vagina 
or rectum. As previously discussed, microbicide development has mainly 
focused on HIV-1 as a single target. HIV-1 microbicides have ranged from 
Tenofovir gel (clinical trial CAPRISA 004) to preventative oral administration of 
ARVs including TDF and FTC (VOICE clinical trial)47,156,176. And PrEP, while not a 
topical microbicide, has become the latest prophylactic available on the market 
that provides protection against the sexual transmission of HIV-1. Similarly, 
single-target microbicides for T. vaginalis have also been explored. Like PrEP, 
oral metronidazole has been tested as a microbicide but an insignificant 
difference in pathogen clearing time was achieved. Similar results were found 
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with vaginally administered metronidazole, although there was symptomatic 
relief for women who presented with trichomoniasis symptoms177,178. A 
promising antimicrobial peptide was also developed in the early 2000s that 
demonstrated impressive microbial properties against T. vaginalis in a murine 
model, known as D2A21. D2A21 protected 90%< of mice from protozoal 
adherence to vaginal epithelial cells. D2A21’s development was discontinued for 
Trichomonas vaginalis; interestingly, it is currently in Phase III clinical trials as an 
antibiotic in burn patients177,179.  
In summary, there are multiple approaches and on-going research studies 
focused on preventing the sexual transmission of pathogens. Our lab is 
specifically interested in exploring the use of monoclonal antibodies as topical 
microbicides and contraceptives. This dissertation focuses on the development of 
a multi-pathogen microbicide using HIV-1 and Trichomonas vaginalis as model 
pathogens. 
HIV-1 Transmission and Infection 
HIV-1 is a single-stranded, positive-sense RNA lentivirus responsible for 
chronic infection, ultimately leading to the acquired immunodeficiency 
syndrome (AIDS) (Figure 1-5)55,180. The global HIV/AIDS pandemic began in the 
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early 1980s, and the first form of treatment--an antiretroviral drug known as 
azidothymidine (AZT) that inhibited HIV-1’s reverse transcriptase—was 
approved in 198755,181. Since the beginning of the epidemic, the virus has cost 
approximately 35 million people worldwide their lives, and approximately 37 
million people today are living with HIV globally182.  There are two different 
types of HIV:  HIV-1 and HIV-2. HIV-2 is generally characterized by lower 
transmissibility and a slower, decreased likelihood of progression to AIDS183–185. 
It is predominantly found in West Africa. HIV-1, in turn, with its high infectivity 
and generally quick progression to AIDS when left untreated, is a global 
epidemic186. The scope of this thesis is focused on HIV-1.  
 
 
Figure 1-5- Schematic of a mature human immunodeficiency virus. Image by Thomas 
Splettstoesser (www.scistyle.com) 
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HIV-1 can be sexually transmitted between individuals through exchange 
of bodily fluids including blood, semen, and vaginal/anal secretions, and 
vertically transmitted between mother and child during pregnancy, at the 
moment of birth, or through breast feeding175,187–189.  Young women, girls, and sex 
workers in particular are disproportionately affected by HIV-1. Young women 
between the ages of 10 and 24 are twice as likely to be HIV-infected than their 
male counterparts. Female sex workers are 12 times more likely to acquire HIV-1 
than non-sex workers190. Globally, over half of the people living with HIV-1 are 
females (~19.1 million), and sexual intercourse with an infected male is the 
primary reason for infection. The risk of HIV-1 infection in male-to-female 
transmission of HIV-1 ranged 0.08-0.30% per sex act; in comparison, female-to-
male transmission ranges from 0.04-0.38% per sex act191–193. Risk of transmission is 
also dependent on viral loads, STIs, and vaginal health or inflammation77,194–197. 
Baggaley et al (2018), in particular, found that gender differences affect the rates 
of HIV-1 transmission with receptive anal risk of transmission in women (3.38% 
per sex act) being significantly higher than in men (0.75%)191,198. Additionally, the 
low rates of sexual transmission per coital act are likely due to the “bottleneck” 
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phenomena that occurs during sexual transmission199. Despite the high genetic 
diversity of HIV-1 found in infected individuals, only a few ‘transmitter- 
founder’ (T/F) viruses are responsible for establishing infection in the new host. 
These viruses have unique genotypic and phenotypic characteristics that enable 
the pathogen to be successfully transmitted from the donor to the recipient. 
Selection factors resulting in a T/F can include: 1) blood/genital tract genetic 
compartmentalization leading to distinct viral diversity in the MRT and (albeit a 
little more inconsistently) in the FRT; 2) The infected patient’s genital fluid which 
may contain lectins or autologous antibodies that prevent the transmission of 
specific viruses to the recipient; 3) Glycosylation on Env protein, where less 
glycosylation is associated with increased likelihood of transmission, particularly 
evidenced in HIV-1 Clades A, C, and D. 4) Availability of target cells in the 
recipient’s mucosa that encourage replication, such as activated CD4+ T cells; 
and 5) “genotype fitness” of the virus that determines viral characteristics such 
as IFN-resistance (secreted by vaginal epithelial cell) and the rapid replication 
needed to establish infection199,200. 
HIV-1 targets CD4+ cells in humans, leading to their depletion and 
consequently compromising the host’s immune system. Figure 1-6 summarizes 
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the virus’ replication cycle within a CD4+ T cell. Briefly, the V3 loop on HIV-1’s 
gp120 binds to CD4 on the target cell. Binding causes a gp120 conformational 
change which enables the subsequent binding of Env to CXCR4 or CCR556,59. 
After co-receptor binding, the virus’s gp41 proteins facilitate the fusion of the 
viral envelope with the cell’s plasma membrane. Upon entering the cell, viral 
RNA is uncoated and reverse transcribed into DNA with a viral reverse 
transcriptase. The newly synthesized DNA is then integrated into the host cell’s 
DNA where it becomes a provirus. The provirus can remain in the host cell 
without continuing the replication cycle, resulting in latency and chronic 
infection55,201. HIV-1 relies heavily on its host cell to aid in its replication: when 
the provirus undergoes transcription, viral RNA is remade and exported into the 
cytoplasm. There, viral proteins are translated and all viral components are 
assembled at the plasma membrane. The virus buds from the cell surface; full 
viral maturity is only reached upon protease activity, otherwise the virus 
remains non-infectious55,201,202.   
Figure 1-7 depicts male-to-female transmission of HIV-1 through the 
vaginal tract as an example of mucosal transmission of the virus203. Semen 
contains both free HIV-1 virions (cell-free transmission) and HIV-1 infected 
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CD4+ T cells, and to a lesser extent, macrophages (cell-associated 
transmission)188,204. Upon entering the vagina, cell-free transmission is established 
if the virus penetrates the stratified epithelial or simple columnar cell barrier102,164. 
While formidable, this barrier is not impenetrable115. As previously mentioned, 
the TZ is susceptible to infection by R5-tropic HIV-1 due to the  thinning of the 
epithelial layer and the high expression of CCR5 on CD4+ T cells prevalent in the 
lamina propria directly beneath the epithelial barrier83,85,117. Inflammation or  
lesions in the tissue can also facilitate virus penetration through the epithelial 
layers into the lamina propria where CD4+ target cells are found115,203.  Dendritic 
cells not directly infected by HIV-1, can capture the virus with surface proteins 
such CD169 and DC-SIGN104,105,205,206. These cells bind HIV and inadvertently 
shuttle the virus through the epithelial barrier where it encounters local CD4+ T 
cells and macrophages, establishing a local infection164,180,203,207. Completely 
penetrating the epithelial barrier, nonetheless, is not always necessary to 
establish local infection. Vaginal epithelial dendritic cells, found in the 
epithelium rather than the lamina propria, have been shown to be R5 HIV-1 cell 
targets and can potentially  play a role in establishing infection 104.  The newly 
infected cells or virus-carrying APCs can subsequently migrate to the lymph 
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nodes where CD4+ cells are readily found and infection will disseminate 
systemically.   
Cell-associated HIV-1 transmission is expected to be 100-1,000-fold more 
efficient than infection by cell-free virus208,209. In male-to-female HIV-1 
transmission, cell-associated infection is attributed to seminal leukocytes, such as 
T cells and macrophages, ubiquitously found in semen (Se)210. HIV DNA PCR 
was used to quantify HIV infected cells in semen, and the prevalence of infected 
cells ranged between 21-65%, with up to 80,000 copies/mL found in some 
samples210–213. Presence of productive, infectious virus from seminal leukocytes 
was successfully determined in vitro214,215. Cell-associated transmission in the FRT 
can occur when HIV-infected cells adhered to epithelial tissues via ICAM-1 (or E-
Cadherin)- β-integrin interactions 210,216–218 and release virions towards the 
epithelium210,219. The subsequent transcytosis of virus across the epithelial barrier 
facilitates productive infection of underlying CD4+ cells. Additionally, cell-to-cell 
transmission can occur in the FRT tract as 1) infected seminal leukocytes 
encounter female tract CD4+ target cells in the tissue or 2) transmigrate through 
the epithelium into the lamina propia disseminating infection220–222.  Infected cells 
can directly transfer infection to bystander target cells via the formation of 
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virological synapses. Cell-to-cell adhesion molecules stabilize the formation of 
the synapse initiated by CD4-gp120 interactions between an uninfected and 
infected cell220,223. The virological synapse then allows for the directed transfer of 
HIV-1 particles between cells and protects the virus from the host’s immune 
response, such as broadly neutralizing antibodies (bnAbs)220. 
 
Figure 1-6- HIV-1 replication cycle. The figure depicts the major steps of viral replication 
including fusion, uncoating, reverse transcription, integration, transcription, translation, 
assembly, release, and maturation. Green boxes indicate ARV targets. Reprinted with the 
permission from: Barré-Sinoussi, Ross, & Delfraissy, (2013).  Nature Reviews Microbiology 
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Figure 1-7- Schematic of HIV-1 infection. Infection is established when free virus or infected 
cells penetrate the FRT epithelial barrier and infect a founder population of cells in the lamina 
propia or interact with a carrier APC. The infected cells will then expand and disseminate 
establishing systemic infection. Image adapted from Haase, (2010). Nature with help from 
BioRender 
 
Trichomonas vaginalis Transmission and Infection 
Trichomonas vaginalis is a prevalent STI pathogen first discovered in 
1836224. T. vaginalis (TV)  is a parasitic protozoan that is typically 10-20 µm long 
and approximately 2-14 µm wide (Figure 1-8, left panel)225,226. The anaerobic 
parasite is flagellated and usually pear-shaped in its free swimming form, 
replicating by longitudinal binary fission (Figure 1-8, right panel)226. Humans are 
the only known hosts of TV and approximately 70% of cases are 
asymptomatic173,225,227,228. Until recently, TV was easily cured with metronidazole 
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but resistance to this only form of treatment has emerged81,229. While men are 
likely to clear the infection in days, infection in women can persist for years. 
Chronic infection can result in reproductive pathologies including preterm 
delivery, pelvic inflammatory disease, and increased susceptibility to HIV-1 
infection81,230. Reasons for the disparity of infection between sexes is unclear with 
increased iron in the FRT due to menses being the primary hypothesis231,232.  
 
 
Figure 1-8- Trichomonas vaginalis structure and reproductive cycle. Left panel depicts 
Trichomonas vaginalis morphology (Image taken from http://bioweb.uwlax.edu/). Right panel 
depicts Trichomonas vaginalis replicate cycle. Longitudinal binary fission happens both in free 
swimming and adhered protozoa, adapted from the CDC233.  
 
TV infection occurs when the free swimming pyriform of Trichomonas 
vaginalis comes into contact with vaginal epithelial cells in the female 
reproductive tract226,234. In a process not quite fully understood, the protozoa 
adhere to the vaginal epithelial cells and become amoeboid morphologically. The 
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only surface molecules on epithelial cells known to mediate attachment, 
Galactin-1 and Galactin-3, interacts with TV’s lipophosphoglycans (LPG)228,235,236. 
The recent sequencing of TV’s genome and subsequent protein studies show 
BspA-like proteins may mediate TV’s adherence to epithelium. BspA proteins are 
a class of surface adhesion proteins of Bacteroidals with Leucine-rich repeats237–
239.  Finally, TV adhesion proteins AP65, AP51, AP33 and AP23, have also been 
shown to mediate attachment to vaginal epithelial cells (VEC) in vitro. Antibodies 
blocking these proteins decrease adherence to epithelial cells. These adhesion 
proteins, interestingly, do not play a role in the pathogen’s specificity to VEC240 
Nevertheless, once adhered, T. vaginalis phagocytoses host epithelial cells, 
surrounding microbiota, and even immune cells. The protozoa are also known to 
secrete serine and cysteine proteases to break down the epithelial cells’ 
extracellular matrix further, facilitating parasite adherence and mobility. TV’s 
phagocytosis of host cells and vaginal microbiota enable its survival in, what is 
for them, a nutrient-scarce environment. Phagocytosis of cells and bacteria 
provides basic macronutrients needed for survival. Due to the pathogen’s low 
production of lipids, it particularly relies on bacteria and eukaryotes as an 
exogenous source228,237. Finally, phagocytosis of Lactobacillus sp. increases the 
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lumen’s pH making it slightly more basic; TV survival and proliferation are 
optimal at pH 6241–243. Despite the presence of phagocytosing parasites and the 
resulting cellular damage, T. vaginalis causes only a mild, barely perceptible 
inflammatory response225,228,229,244. T. vaginalis’ consumption of local microbiota 
and the decreased integrity of the epithelial layer as a result of infection, make 
the vaginal tract more vulnerable to sexually transmitted pathogens including 
chlamydia, and gonorrhea. In particular, it is known to increase the rates of HIV-
1 infection 2-3 fold, making this pathogen a global concern77,228,231. 
 
Monoclonal Antibodies as MPT Candidates 
History of Monoclonals as Contraceptive Candidates 
In the mid-1980s, the WHO sponsored two workshops to identify sperm 
and trophoblast specific antigens with the intention of finding suitable antigens 
for a contraceptive vaccine. Over 29 laboratories submitted over 100 monoclonal 
antibodies (mAb), out of which only three antisperm antibodies and two anti-
trophoblast antibodies were found to display sufficient tissue specificity245. Public 
health interest in a contraceptive vaccine eventually declined as this approach is 
considered irreversible, but monoclonal antibodies (mAbs) as contraceptive and 
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microbicidal agents still have considerable potential, especially in the case of 
HIV-1 where no cure or vaccine exists65,174.  
Antibodies for Clinical Application 
Therapeutic monoclonal antibodies have recently become popular for 
treating a wide range of diseases. There are currently over 70 FDA-approved 
mAbs for various clinical applications175,246,247. Due to genetic engineering, 
antibodies can be completely human or humanized, allowing for repeated 
dosage and continuous treatment due to low immunogenicity and the avoidance 
of “serum sickness”248. Antibodies that contain different heavy chains, belong to 
different isotypes (Figure 1-9). The Fc portion of each isotype provides the 
antibody with different effector functions subsequently affecting how the rest of 
the immune system engages with a given pathogen. IgG1, for example, can bind 
complement through the classical pathway, engage mononuclear cells in 
Antibody Dependent Cell-Mediated Cytotoxicity (ADCC), and enable efficient 
phagocytosis249,250. The abundance of IgA in genital secretions indicates that this 
isotype is well-suited for mucosal protection249. IgA efficiently entraps pathogens 
in the mucosa and prevents them from reaching their target cells251. IgA 
(specifically secretory IgA) is also highly resistant to proteases abundantly found 
  
47 
in FRT and has documented ADCC engagement with neutrophils. Both IgG and 
IgA antibodies also encourage phagocytosis through opsonization, facilitating 
pathogen clearance148,252. Finally, both IgG and IgA antibodies can also directly 
neutralize pathogen. This mechanism is best exemplified in HIV-1 broadly 
neutralizing antibody, VRC01, which binds to HIV-1’s surface protein gp120 
preventing it from binding to its CD4 receptor target cells and establishing 
infection. While the antibody has a direct neutralizing effect on the pathogen, the 
antibody’s Fc can continue to engage with receptors on effector cells as described 
above253. While HIV-1 infected human patients have predominantly IgG broadly 
neutralizing antibodies, IgA bnAbs have also been documented253,254.  These 
characteristics make both of these antibody isotypes potential candidates for 
targeting bacteria and viruses in mucosal tissues.   
Isotypes can, therefore, be strategically used and antibodies can be 
engineered to have high potential as a topical microbicide, contraceptive, or 
multipurpose prevention technology. Furthermore, an antibody based MPT with 
fully human antibodies promises low immunogenicity, especially when topically 
applied to the vaginal tract instead of systemically248. Evidence for the 
effectiveness of antibodies in mucosal tissues is already found in vivo where 
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studies have shown that broadly neutralizing antibodies (bnAbs) can prevent 
transmission of low-titer SHIV255. Furthermore, antibodies are versatile and can 
work alongside other antibodies, small molecules, and biologics without losing 
activity. This collaborative property makes mAbs excellent candidates for an 
MPT. Mab treatments, however, can be expensive, limiting MPT accessibility; 
new technologies and antibody producing platforms can help circumvent this 
limitation.  
 
 
Figure 1-9- Schematic of antibody isotypes. Image adapted from absoluteantibody.com. 
 
Production Platform for Monoclonal Antibodies 
Nicotiana sp. was first described as an antibody production platform in 1989256–260. 
Interest in this alternative plant-based platform resulted from an interest in 
decreasing antibody costs and production times, and increasing overall 
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production256,261. At the time, antibodies produced in mammalian cells (like first 
generation Chinese hamster ovary [CHO] cells) took approximately 40 days to 
manufacture and cost between $50-100/g to produce. Using Nicotiana, the whole 
production process, from transfection to antibody purification, takes 10-12 days 
and the resulting antibodies cost ~$20/g (MappBio, personal communication)261. 
In addition to shortened manufacturing timelines and decreased production 
costs. Nicotiana is an attractive production platform due to the ease of genetic 
manipulation with Agrobacterium sp256,259,261,262.   
Agrobacterium tumefaciens is transformed with heavy and light chain 
plasmids of the desired antibody. The transformed bacteria are then sprayed 
onto the leaves of Nicotiana where they transfect the plant. Bacterium attachment 
to plant cells is still poorly characterized, but the bacterium’s flagella and 
unipolar polysaccharide A (UPP) have been implicated. The wounded plant cells 
secrete phenolics, hormones, and saccharides that are detected via bacterium 
membrane sensor protein, VirA, and the sensor protein in the cytoplasm, VirG. 
Once the VirG is phosphorylated, the process to transfer the transformed DNA 
from the bacterium to the plant begins. Downstream Vir proteins (such as VirB), 
activated by interactions with VirA and VirG, result in the formation of the type 
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IV secretion system (T6SS). T6SS is responsible for shuttling the plasmid DNA 
from the bacterium into the plant cell. The plasmid is accompanied by bacterial 
proteins that subsequently process the T-DNA (transfer DNA) so that it is 
imported and integrated into the plant cell nucleus and subsequently translated 
(Figure 1-10)263. The transfected leaves produce antibody over the course of a 
week. Leaves are then crushed and the antibody purified from the pulp using 
Protein A sepharose beads264,265. The ease of genetic manipulation of Nicotiana 
also allows for the establishment of glycan homogeneity. Plant-specific 
glycoforms, such as those containing fucose and xylose, can be easily knocked 
down in the antibody-producing leaves through RNAi, permitting a 
homogenous humanized glycosylation of antibodies261,262. Since glycosylation is 
known to affect antibody Fc function, any changes in glycosylation might result 
in decreased antibody stability or interfere with ADCC or antibody-complement 
activity266,267. By ensuring homogenous glycosylation on plant-derived human 
antibodies, the resulting antibodies will have decreased immunogenicity and 
predictable, consistent performance, and thus constitute a widely accessible 
MPT. 
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Figure 1-10- Agrobacterium transfection of Nicotiana. Image depicts all 5 steps of Agrobacterium 
expression of a transformed plasmid. Image adapted from Hwang (2017), The Arabidopsis Book.  
 
CD52g as an Antibody Target for MPTs 
One of the protein targets submitted to the WHO workshop, CD52g, was 
targeted by an anti-sperm antibody that demonstrated high specificity and 
efficiently blocked sperm function245,268,269. CD52g is a GPI-anchored glycoprotein 
produced in the male reproductive tract (MRT) by epithelial cells lining the 
caudal epithelium, the vans deferens, and urethra270. CD52g—also known as 
CD52w, SAGA-1, seminal CD52 I and II, and CD52mrt—is a 12 amino acid long 
protein identical to the lymphocyte GPI-anchored protein, CD52268,271,272. The 
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distinguishing characteristic between these proteins is their N-linked glycans 
(Figure 1-11A)268. Sperm antibodies with high specificity distinguish between the 
two different glycosylation patterns despite the identical peptide sequence. 
CAMPATH, commercially known as Alezitumab, is able to detect the amino acid 
backbone on both CD52g and CD52 (Figure 1-11B)273,274. 
 
  
Figure 1-11- Comparing CD52 and CD52g structure and Anti-CD52g specificity. A) A diagram 
of the CD52g protein. The plasma membrane is depicted in green and the GPI anchor is 
highlighted in red. The identical 12 amino acid protein core is depicted on both CD52 and CD52g. 
The green circles depict CAMPATH targets. Blue boxes highlight the N-linked glycosylations of 
both proteins. B) Silver staining of sperm lysates with anti-sperm specific antibodies. S19 and H6-
3C4 only detect CD52g not CD52, despite structural similarities. Figures adapted from Herr, 1999. 
CD52g is uniquely produced by epithelial cells in the MRT, yet is found 
coating the heads and tails of mature sperm cells274,275. The GPI anchor of CD52g 
provides the protein with the hypermobility needed to reach its target cell276–278. 
The exact mechanism of protein transfer is unknown. CD52g is found in soluble 
form in seminal plasma (SP), and it is likely that soluble CD52g can be found on 
seminal extracellular vesicles and transferred to sperm and other phospholipid 
A) B) 
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bilayers,  like human lymphocytes279. Additionally, as sperm mature and migrate 
along the MRT, CD52g can “flip” onto their plasma membranes from direct 
contact with CD52g+ epithelial cells (Figure 1-12)280. Similarly, the function of 
CD52g is unclear, but it is thought to be involved in sperm maturation275,281, 
immune (complement) protection of sperm in the FRT271,279, and the coagulation 
and liquefaction of semen282, a phenomenon thought to improve sperm mobility 
in the FRT.  
 
Figure 1-12- CD52g transfer mechanisms. Mechanisms of CD52g membrane transfer. 1) Depicts 
GPI anchor flipping due to physical contact of plasma membranes. 2) Lipid carrier hypothesis, 
little evidence has supported this hypothesis since the 1990s. 3) Hypothesis of extracellular 
vesicular transfer. Image adapted from Diekman, (2001).  
 
Isojima’s laboratory in Japan was the first to characterize an anti-sperm 
antibody. The IgM antibody, H6-3C4, was isolated from a peripheral blood B cell 
isolated from a woman with infertility283.  In 1999, John Herr published a mouse 
IgG hybridoma based on Isojima’s work and patented the antisperm antibody, 
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S19245,268. It was later determined that H6-3C4 and S19 both target CD52g272. Upon 
exposure to these antibodies, sperm agglutinate leading to sperm immobility 
and, in the case of Isojima’s patient, infertility. This agglutinating property can be 
harnessed for contraception. In the early 2000s, the idea of a topical contraceptive 
and microbicides regained traction, eventually leading to the production of the 
“Human Contraceptive Antibody” (HCA)43,284–286.  HCA is the fully human IgG1 
version of Isojima’s H6-3C4 produced in Nicotiana benthamiana. Our lab 
collaborates with MappBio, the biopharmaceutical company producing HCA, in 
order to explore its potential as a female topical contraceptive and broad-
spectrum microbicide.  
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Dissertation Objectives 
Two major problems associated with reproductive health in women are 1) 
high prevalence of unplanned pregnancies and 2) sexually transmitted 
infections.  In recent years, ~40% of pregnancies worldwide were unplanned 
despite multiple contraceptive products being available on the market 
demonstrating a gap in contraception use9,13.   Additionally, the World Health 
Organization estimates that 360 million treatable sexually transmitted infections 
are acquired annually and close to 1.2 billion people are living with a chronic 
viral infection77. This demonstrates an unmet need for improved STI protection. 
A readily accessible, easy-to-use, discreet multipurpose prevention technology 
combining contraception and microbicide protection is therefore needed 
globally. 
In recent years, there has been a global effort to develop microbicides 
(compounds that neutralize or kill sexually transmitted viruses and bacteria in 
the vagina or rectum) for use as MPTs. Two recent phase III clinical trials, the 
RING and ASPIRE studies, used vaginal rings that release antiretroviral drugs 
(ARVs) to prevent male-to-female sexual transmission of HIV-1. The results, 
published in 2016, demonstrated a 37% general decrease in the risk of HIV-1. 
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Final interviews from these clinical trials highlighted the participants’ interest in 
adding a contraceptive component to the product48,72.  Our laboratory’s goal is to 
develop an MPT that will provide contraception and protection against various 
STI pathogens through the use of Nicotiana plant-derived humanized monoclonal 
antibodies (mAbs-N)284. 
A mAb-N being investigated by our lab for MPT use, the Human 
Contraception Antibody (HCA) is directed against CD52g, a sperm antigen 
originally identified in patients with infertility and studied for its contraceptive 
properties269,283. CD52g is a GPI-anchored, N-linked glycoprotein produced by 
epithelial cells in the male genital tract270. This ~25 kDa glycoprotein is secreted 
into seminal plasma and is embedded into the plasma membrane of sperm cells. 
Anti-CD52g-N rapidly induces sperm agglutination in vitro suggesting 
contraceptive properties. In addition, our preliminary studies also indicate that 
CD52g inserts into the phospholipid bilayer of somatic (non-sperm) cells in 
semen, such as HIV-infected leukocytes and STI pathogens (e.g. Trichomonas 
vaginalis) making it a potential target for the prevention of STI pathogens. Based 
on these findings we hypothesize that topical use of CD52g-targeting antibodies 
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may provide contraception and broad protection against several STI 
pathogens. 
Aim 1- Investigate the contraceptive effects of HCA-N 
 
“Human Contraceptive Antibody” (HCA-N), a human monoclonal antibody 
specific for CD52g, has previously been shown by our lab to potently agglutinate 
human sperm. We are interested in developing this antibody as a topical 
contraceptive and plan to investigate its contraceptive properties in 
physiologically relevant in vitro conditions. 
 
Hypothesis: HCA will effectively agglutinate sperm despite donor-to-donor 
variability.  As a topical contraceptive, HCA will be able to withstand the low pH 
conditions of the vaginal tract.  
 
Aim 2- Investigate whether CD52g anchors into the sexually transmitted 
pathogens HIV-1 and Trichomonas vaginalis and whether HCA treatment 
prevents transmission of disease. 
 
Due to the hypermobility of GPI anchored proteins, CD52g can potentially 
transfer to the phospholipid bilayer of HIV-1 enveloped virions, infected 
lymphocytes, and Trichomonas vaginalis. The agglutinating property of HCA 
could potentially agglutinate the pathogens preventing transmission of disease. 
 
Hypothesis: CD52g will be found on the surface of HIV-1 and Trichomonas 
vaginalis. HCA treatment will lead to the direct agglutination of pathogens, 
preventing STI transmission or co-agglutination with sperm in semen. 
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Chapter 2 - Production and characterization of a human antisperm monoclonal 
antibody for topical contraception in women 
 
In lieu of this chapter I have submitted the manuscript submitted to Science 
Translational, but formatted for this dissertation 
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Introduction 
         At least 40% of all human pregnancies worldwide are unplanned13, 
indicating a need for more family planning education, contraceptive availability, 
and product diversity. Currently, the most widely used reversible contraceptives 
are barrier methods, which have a high degree of user failure, and hormonal 
methods, which are often discontinued due to side effects3,28,34,287.  A low-risk, 
non-hormonal, on-demand, discreet, woman-controlled method could provide 
an important contribution to the contraception field. Furthermore, this approach 
could garner even wider acceptance if incorporated into a multipurpose 
prevention technology (MPT) product that not only provides contraception, but 
also affords protection against the human immunodeficiency virus (HIV) and 
other sexually transmitted infections (STIs). 
Antisperm antibodies are commonly detected in the sera and genital 
secretions of infertility patients and are thought to impede conception by 
agglutinating, trapping in mucus, and/or immobilizing sperm288–291. One 
antisperm antibody found in infertility patients is directed against a low 
molecular weight male reproductive tract (MRT)-specific glycoprotein, CD52g292. 
The antigen is expressed and secreted by epithelial cells lining the lumen of the 
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epididymis, and to a lesser extent the vas deferens, and seminal vesicles269. The 
CD52g protein core is a 12 amino acid peptide sequence, CD52 (CAMPATH-1 
antigen), also expressed by lymphocytes293.  The difference between the MRT and 
lymphocyte forms of CD52 is a unique N-linked glycan (g), which is present only 
on the MRT protein. This unique glycan can be specifically targeted by antisperm 
antibodies268. CD52g also has a glycosylphosphatidylinositol (GPI) anchor that 
enables its incorporation into the plasma membrane of sperm as they transit the 
epididymis268.The glycoprotein is also found in soluble form in seminal plasma 
(SP) and in semen exosomes279,294. While the exact function of CD52g is unknown, 
it has been implicated in sperm maturation, protection of sperm from immune 
responses in the female reproductive tract, and the coagulation and liquefaction 
of semen271,275,281,282,295. 
H6-3C4, the first reported monoclonal antibody directed against the N-
linked glycan epitope on CD52g, was developed by Isojima et al. using 
immortalized B-cells from a woman with infertility and a high titer of sperm-
immobilizing antibodies283. Mouse monoclonal antibodies that react with the 
CD52g MRT-epitope have also been developed, including 2C6296,297 and S19298,299.  
These, and other antisperm mAbs, were submitted from various laboratories 
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worldwide for evaluation by a World Health Organization (WHO)-sponsored 
antisperm vaccine workshop in 1987. The anti-CD52g antibodies scored very 
well in functionality and specificity tests, and the CD52g sperm antigen was 
identified as a potential contraceptive vaccine candidate245.  Interest in antisperm 
mAbs has recently re-emerged due to the introduction of new commercially-
viable mAb production platforms, and the possibility that passively 
administered mAbs, unlike a vaccine, could constitute a reversible contraceptive 
method. Antisperm mAbs could be used in vaginal products, such as films and 
rings for contraception, and combined with microbicidal agents to provide 
multipurpose protection against unplanned pregnancy and sexually transmitted 
pathogens. In other words, a multipurpose prevention technology (MPT)300. 
Our research team used a modification of the H6-3C4 sequence to 
manufacture a human antisperm mAb in Nicotiana benthamiana plants, a platform 
used for the production of mAbs and other proteins for clinical applications264,301. 
We have designated this antibody the “Human Contraception Antibody” (HCA). 
In this report we describe the manufacture of HCA, its specificity, and its 
performance in sperm functional assays.  
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Materials and Methods 
Study Design 
This study was designed to assess the potential of HCA as a topical contraceptive 
by evaluating its specificity and efficiency in physiologically relevant conditions 
in vitro. HCA is an antisperm mAb, once associated with infertility and adapted 
as a contraceptive antibody. We determined agglutination efficiency via the time 
HCA took to agglutinate sperm in various conditions, as well as measuring the 
progressive sperm that escaped agglutinates after mAb treatment. Experiments 
were replicated a minimum of three times, with two to three trials conducted for 
each data point. Donor variability was taken into account with a minimum of 
three study participants being used for the Agglutination Kinetic Assay and 
Sperm Immobilization tests, and six study participants used for the Sperm 
Escape Assay. For all experiments, semen samples met WHO semen 
parameters302. For the Agglutination Kinetics Assay, the 120 second limit to 
determine agglutination was selected since literature studies show sperm can 
reach the endocervix post insemination or ejaculation between 3-5 minutes303–305; 
we wanted to be under this threshold. Because the assay depends on 
observation, two semi-blinded, trained technicians observed agglutination to 
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avoid bias. Investigators were not blinded for the Sperm Escape Assay. For the 
Luminex panel, if a replicate of a given cytokine was above or below the level of 
detection (after modifying sample dilutions), it was excluded from analysis. 
Control tissues were run in duplicate while experimental tissues were run in 
triplicate. Because S19 is a patented, commercialized agglutinating antibody, it 
was used as a control until HCA demonstrated faster agglutination, then it was 
excluded from further experiments due to sample limitations and sperm 
viability. 
Antibodies   
Human Contraceptive Antibody (HCA) 
The human anti-CD52g mAb was produced by Mapp Biopharmaceutical Inc. 
(San Diego, CA, USA) from the sequence of H6-3C4, a human antisperm 
mAb292,306. Genes containing the variable region sequences of H6-3C4 were 
synthesized (Life Technologies; San Diego, CA, USA) and subsequently cloned 
into TMV and PVX plant expression vectors307 containing codon-optimized 
human lambda and human IgG1 constant regions. The vectors were then 
transformed into Agrobacterium tumefaciens strain ICF320 (Icon Genetics; 
Halle/Saale, Germany). Nicotiana benthamiana plants, genetically modified to 
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produce mammalian N-linked glycans301, were grown for four weeks in an 
enclosed growth room (20-23°C) and used for vacuum infiltration as previously 
described264.  Seven days post-infiltration, antibody was extracted from the leaf 
tissue and purified by Protein A chromatography as previously described 264,265. 
The IgG1 HCA was aliquoted and stored at -80°C.  
 
S19 
Mouse anti-CD52g mAbs were obtained from the supernatant of MHS-8 
hybridoma cells originally established by John Herr (HB-12144, ATCC)269,272,308. 
Healthy MHS-8 hybridomas were grown in complete Isocove’s Modified 
Dulbecco’s Medium (IMDM) (ATCC Manassas, VA, USA) with 10% fetal bovine 
serum (FBS), 1% Penicillin Streptomycin, 1% L-Glutamine 200 mM (Gibco, 
ThermoFisher Scientific, Waltham, MA, USA). For antibody collection, 
hybridomas were seeded at confluency in IMDM without FBS and cultured until 
cells died309. The supernatant was collected and concentrated with a 15 mL, 50-
kDa centrifuge filter (UFC905096, Millipore Sigma, Burlington, MA, US) at 3,000g 
for 40 minutes. Concentrated antibody was washed twice with fresh IMDM, 
spinning the filters each time at 3,000g for 30 minutes.  S19 antibody was 
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resuspended in PBS and quantified by nanodrop. Antibody was stored in 
Multipurpose Handling Media (MHM; FUJIFILM Irvine Scientific; Santa Ana, 
CA, USA) at 4°C. 
  
CAMPATH-1 
CAMPATH-1 is a commercially available rat mAb, clone YTH34.5, directed 
against a peptide epitope on CD52 (MA5-16999, ThermoFisher Scientific, 
Waltham, MA, USA). 
Tests of Antibody Specificity 
Immunofluorescence Assay 
Anti-CD52g mAbs were tested for specificity on washed human spermatozoa 
and human peripheral blood mononuclear cells (PBMCs, negative control). Cells 
were air dried on slides, fixed with acetone, and incubated with 25, 50 or 100 
µg/mL of HCA, S19 or CAMPATH mAbs. VRC01-N, a human IgG1 mAb 
produced in Nicotiana and directed against the HIV-1 envelope glycoprotein 
gp120, was used as an isotype-matched negative control antibody for HCA.  A 
mouse mAb directed against CD3, a prominent T lymphocyte surface protein 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as an isotype-
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matched control antibody for S19. Primary antibodies were detected with a 1:200 
dilution of fluorophore-conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories Inc, West Grove, PA, USA). Coverslips were 
mounted on slides with Antifade Mounting Medium with DAPI (Vector 
Laboratories, Burlingame, CA, USA)  
 
Immunohistology 
Antibodies were tested for reactivity on a variety of human reproductive tract 
tissues (cauda epididymis, vas deferens, vagina) and tonsil.  Paraffin-embedded 
tissues were sectioned at 5 µm, de-waxed, hydrated and subjected to an antigen 
retrieval step. Antigen retrieval was carried out by immersing the sections in a 
citrate buffer (pH 6) and then placing the tissues in a pressure cooker that was 
heated to 125°C for 30 seconds (Biocare Medical, Concord, CA). The sections 
were incubated with Cy-3 labelled HCA or VRC01 (conjugation kit: Abcam, 
Cambridge, MA, USA) at a 1:20 dilution overnight at 4°C. Finally, the sections 
were mounted in an anti-fade medium containing DAPI, as a nuclear counter 
stain. All sections were examined under an Olympus microscope (Olympus 
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America Inc. Melville NY) fitted with epi fluorescence imaging and images were 
captured with a digital camera.   
   
Scanning Electron Microscopy (SEM) 
Sperm that had been treated with HCA or PBS (control) were air dried on 
coverslips and fixed in ½ strength Karnovskys fixative for 48 hours. Coverslips 
were then rinsed in PBS and dehydrated in a series of ethanol concentrations- 
35%, 50%, 70%, 95% (1x for 10 minutes) and 100% (3x for 10 minutes) before 
critical point drying in a Tousimis semi-automatic Critical Point Dryer. 
Coverslips were mounted on aluminum stubs and coated with chromium in a 
GATAN Ion Beam Coater. Images were taken with a JEOL 7401F Field Emission 
Scanning Electron Microscope.  
 
Western Blot 
Human sperm (SC), SP, and PBMCs were lysed in radioimmunoprecipitation 
assay (RIPA) buffer and used as antigen targets in the western blot assay. For 
denatured blots, 20-30 µg of protein were denatured with SDS.  Samples were 
loaded onto a 4-15% gradient polyacrylamide gel (4561084, Bio-Rad, Hercules, 
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CA, USA), and after electrophoresis, proteins were transferred to PVDF 
membranes. The blots were blocked with 5% powdered milk and washed with 
0.1% TBS-T. All primary antibodies were used at a concentration of 10 µg/mL; 
anti-mouse and anti-rat secondary antibodies were used at a 1:20,000 dilution, 
and the anti-human secondary antibody was used at a 1: 5,000 dilution (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). Blots were developed in ECL 
substrate (ThermoFisher Scientific, Waltham, MA, USA). To cleave the N-linked 
glycan epitope, sperm lysates were treated with PNGaseF according to the 
manufacturer’s protocol (New England Biolabs, Ipswich, MA, USA). Native blots 
were run similarly in Towbin Buffer without SDS. 
Tests of Antibody Function 
Semen Analysis and Sperm Preparation 
Healthy men between the ages of 18-45, with sperm samples meeting the 5th 
edition of the WHO’s human semen characteristics for fertility provided the 
semen samples used in this study. This study was approved by the Boston 
University Medical Campus Institutional Review Board.  Participants provided 
written informed consent for the study.  The samples were processed within one 
hour of collection, after liquefaction. Live sperm were separated from the rest of 
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the sample by passage through 90% ISolate density gradient medium (FUJIFILM 
Irvine Scientific; Santa Ana, CA, USA). Briefly, whole semen was layered over an 
equivalent volume of Isolate. The sample was centrifuged at 300g for 20 minutes, 
and the pellet containing live, motile sperm was resuspended in MHM. Sperm 
count and motility were assessed by Computer Assisted Software Analysis 
(CASA; Human Motility II software, CEROS II, Hamilton Thorne).  Both whole 
semen and washed sperm were used for the functional assays described below. 
 
Agglutination Kinetics Assay 
Antibody was diluted in MHM. Two microliters of sperm suspension were 
pipetted and evenly spread on a 9mm well microscopy slide (ThermoScientific, 
Waltham, MA, USA), and an equivalent amount of antibody was added. 
Antibody and sperm were mixed by quickly pipetting three times and sperm 
agglutination was observed in real-time on an Olympus inverted microscope. 
“Time to 100% agglutination” is the time elapsed for the sperm cells visible in a 
single 10x field to become completely agglutinated. Agglutination was timed and 
recorded by two trained independent readers. A minimum of three replicate 
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reads was conducted for each data point.  The assay was repeated a minimum of 
three times using different donor samples. 
 
Sperm Escape Assay 
A modified sperm swim-up assay was used to assess the number of free-
swimming sperm following treatment with HCA. MAbs were diluted in MHM, 
and 30 µL were added to upright 0.2mL PCR tubes. 30 µL of sample were then 
added to the antibody and mixed three times by pipetting. Tubes were placed at 
a 45° angle and the mixture was incubated for 5 minutes at room temperature 
(RT) to allow agglutinated and immotile sperm to settle towards the bottom of 
the tube. A 2.5 µL sample was taken from the top millimeter of the mixture and 
placed in a 4-chambered slide (Microcell 15424, Vitrolife, San Diego, CA, USA). 
The sample was analyzed by CASA to determine both the total sperm 
concentration and the number of progressively motile sperm that escaped 
agglutination. 
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Complement-Dependent Sperm Immobilization Assay 
Washed sperm with an initial motility >90% were adjusted to a concentration of 
25-40 x106 cells/mL in MHM. Human serum, separated from fresh whole blood 
by centrifugation, was used as the complement source. Heat-inactivated (HI) 
complement (heated to 56°C for 30 minutes) was used as the control.  Five µL of 
complement or HI-complement were incubated with 2.5 µL of sperm suspension 
for 5 minutes at RT. Next, 25 µL of HCA were added in a series of two-fold 
dilutions (3.125 - 0.20 µg/mL) and mixed; 3 µL of the suspension were 
transferred to 4-chambered slides in duplicate and the slides were incubated in a 
humidified chamber at 32°C for 1 hour. Sperm motility was assessed using 
CASA. A minimum of three trials were performed using different donors. 
Testing HCA Activity under Physiological Conditions 
Whole semen vs. washed sperm  
To compare the ability of HCA to agglutinate sperm in whole semen and in 
washed sperm, the semen samples were divided into two fractions: 1) whole 
unprocessed semen, and 2) washed sperm cells processed as described above, 
and resuspended in MHM to the same concentration as that in the original 
semen sample. Semen from two to three donors were pooled for these 
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experiments. Agglutination Kinetics and Sperm Escape Assays were run as 
described above. 
 
Effect of sperm concentration 
Motile sperm were isolated from semen using ISolate, and resuspended in MHM 
at concentrations ranging from 2 to 100x106/mL. 
 
Effect of low pH 
To determine whether HCA withstands the low pH conditions often present in 
the human vagina, the pH of MHM was lowered to 3.5 using D/L-lactic acid 
(Sigma Aldrich, MA, USA).  HCA was incubated in pH 3.5 or MHM with neutral 
pH for 0, 2, 4, and 24 hours at 37oC. Following incubation, the low pH MHM was 
neutralized by addition of HEPES Buffer (Invitrogen) and neat seminal plasma. 
The antibody was then used in Agglutination Kinetics Assays.  
Preclinical Safety Assessment 
MatTek EpiVaginal tissue cytokine response assay 
The EpiVaginal Tissue™ model (MatTek Corporation, Ashland, MA, USA) was 
used to study potential proinflammatory effects of HCA and HCA immune 
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complexes, as previously described310. For this assay, a total of 100 µL of different 
combinations of HCA (100 μg/mL), semen and complement (C’) were added to 
the upper chamber (apical side) of the EpiVaginal Tissue™. Tissues were 
incubated at 37°C for 6 hours after which the antibody/sperm/complement 
suspensions were washed off, and 80 µL of MatTek EpiVaginal Tissue Media 
was added to the upper chamber.  After 24 hours, apical and basal supernatants 
were collected and cytokines were measured using a custom 6-plex ProcartaPlex 
Luminex kit (Invitrogen, ThermoFisher Scientific, Waltham, MA, USA). 
Statistical Analysis 
GraphPad Prism (Version 7.03; GraphPad Software Inc.; San Diego, CA, USA) 
was used for statistical analysis and graphing of data. Data were subjected to 
analysis of variance (ANOVA).  A significant ANOVA was followed by post hoc 
multiple comparison tests. For the Sperm Immobilization test, a t-test, with a 
correction for multiple comparisons, was used. Differences were considered to be 
statistically significant when p<0.05.   
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RESULTS 
HCA Production and Characterization  
HCA Yield 
The “Human Contraception Antibody” (HCA) was produced via 
agrobacterium transfection of Nicotiana benthamiana with the H6-3C4 variable 
region sequence and an IgG1 Fc sequence. The monoclonal antibody (mAb) was 
purified on Protein A columns; concentrations of antibody ranged from 0.4 to 4 
mg/mL. 
Immunohistology and Western Blot Assays 
HCA antigen specificity was ascertained by immunohistology and 
western blot. Both live and acetone-fixed washed human sperm were processed 
with HCA, S19, CAMPATH or VRC01 for indirect immunofluorescence 
microcopy. S19, a once commercialized anti-CD52g, and CAMPATH, a mAb 
specific to the amino acid core of CD52g and lymphocyte CD52, were positive 
antibody controls. VRC01, a Nicotiana produced HIV-1 specific IgG1 mAb, was 
the isotype control for HCA. HCA, S19, and CAMPATH reacted with the entire 
sperm surface-from head to tail. VRC01 showed no reactivity (Figure 2-1A-D, 
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respectively). HCA, S19 and VRCO1 did not react with PBMCs (Figure 2-1E-H) 
whereas CAMPATH did, as expected (Figure 2-1C).  
 
Figure 2-1- Nicotiana benthamiana produced HCA is specific to CD52g on sperm. 
Immunofluorescence of sperm cells with A) HCA antibody, B) S19 antibody, and C) CAMPATH 
antibody. D) VRC01 is an isotype control for HCA. Immunofluorescence of PBMCs with E) HCA 
antibody, F) S19 antibody, G) CAMPATH antibody, and H) VRC01. I) Denatured western blot of 
HCA (left panel) and CAMPATH (right panel). PBMCs are a negative control. HCA reactivity 
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disappeared following treatment with PNGaseF, an enzyme that removes N-linked glycans 
(Spermg-). 
 
           In the western blot assay, HCA detected a ~15-25 kDa band in sperm 
lysates—the expected size of CD52g—which disappeared following treatment 
with PNGaseF, an enzyme that cleaves N-linked glycans and removes the 
carbohydrate epitope on CD52g (Figure 2-1I, left panel). CAMPATH, which 
targets the amino acid sequence of CD52g, also reacted with the ~15-25 kDa band 
in sperm lysates. After PNGaseF treatment of sperm, CAMPATH detected a 
lower MW band representing CD52g without N-glycans (Figure 2-1I, right 
panel). Tissue immunohistology was also used to demonstrate HCA specificity. 
Cy3-conjugated HCA reacted with epithelial cells in the human cauda 
epididymis and its luminal contents containing sperm (Figure 2-2A), but did not 
react with human vaginal or tonsil tissue (Figure 2-2B-C). Cy3-conjugated VRC01 
(isotype control) did not react with any of the tissues (Figure 2-2D-F). 
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Figure 2-2- Nicotiana benthamiana produced HCA is specific to CD52g in male reproductive 
tract tissue. Immunohistology staining of directly conjugated Cy3-labelled HCA (red) in the A) 
human cauda epididymis, B) vaginal and C) tonsil tissue. D-F) VRC01 isotype control staining of 
the same tissues. L= lumen 
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Inhibition of Sperm Function 
Sperm agglutination assay 
At a concentration of 100 µg/mL, the highest concentration tested, HCA 
agglutinated 100% of sperm in under 15 seconds (Figure 2-3A and Figure 2-4C). 
Effective agglutination time varied with HCA concentration; at the lowest 
concentration tested, 6.25 µg/mL, 100% sperm agglutination occurred within 60 
seconds (Figure 2-4C).  At a concentration of 100 µg/mL, S19 agglutinated sperm 
within 30 seconds, whereas CAMPATH and VRC01 did not agglutinate sperm 
(Figure 2-3A). Scanning electron microscopy of HCA-treated sperm revealed a 
mixed agglutination pattern:  head-to-head, head-to-tail, tail-to-tail (Figure 2-3B 
and C).  
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Figure 2-3- HCA rapidly agglutinates washed human sperm A) 100 µg/mL of HCA was added 
to washed sperm cells (100 x10
6
 /mL). Sperm agglutination was monitored using an inverted 
microscope (10X). B) SEM images of PBS exposed sperm and C) HCA agglutinated sperm 
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Sperm escape assay 
We modified the classical sperm swim-up assay to evaluate the number of 
progressively motile sperm that escape from the agglutinates formed when 
sperm is treated with HCA. Following the addition of HCA, agglutinated and 
immotile sperm sink to the bottom of the tube, whereas sperm with progressive 
motility can be detected in the upper fraction of the sperm/antibody suspension 
(Figure 2-4A, left panel). These progressively motile sperm are the antibody 
“escapees” that could potentially fertilize an ovum.  When added to washed 
sperm suspensions, HCA concentrations of >6.25 µg/mL reduced the number of 
progressively motile sperm in the swim-up fraction to 0-3% of the media control 
(Figure 2-4A, right panel). There was a slight increase in the number of escaped 
sperm when HCA was added to whole semen, which contains soluble CD52g. At 
the lowest mAb concentration tested (6.25 µg/mL), 15% progressively motile 
sperm escaped from the agglutinates, compared to media samples. At higher 
mAb concentrations (12.5-100 µg/mL), this number was between 2-5% in whole 
semen (Figure 2-4A). 
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Complement-dependent sperm immobilization  
A modified form of the Sperm Immobilization Test was also used to 
determine whether HCA induces complement (C’)-dependent sperm 
immobilization311,312, a phenomenon cited as an effector mechanism reinforcing 
antibody-mediated infertility. HCA potently agglutinates sperm at 
concentrations ≥6.25 μg/mL; therefore, the highest HCA concentration tested in 
this experiment was 3.125 µg/mL which enabled visualization and quantification 
of C’-dependent immobilization of individual sperm using the CASA.  With 
active human complement, there was a significant decrease in motile sperm 
despite low antibody concentrations (p<0.0001); significant sperm 
immobilization was observed at HCA concentrations as low as 0.78 µg/mL 
(Figure 2-4B). In the presence of heat-inactivated complement, HCA did not 
immobilize sperm; the percent of motile sperm was similar to that of media 
controls across all HCA concentrations.   
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Figure 2-4 HCA agglutinates sperm in physiologically relevant conditions in vitro. A) Left 
panel is a schematic of the Sperm Escape Assay, the modified swim-up assay that measures 
progressive sperm that escape HCA induced agglutination. Right panel is a Sperm Escape Assay 
comparing whole semen and washed sperm cell agglutination. Y-axis depicts the percentage of 
progressive sperm present in the HCA-sperm samples compared to the progressive sperm found 
in the media (no antibody) control. Black bars indicate washed sperm data and red bars indicated 
whole semen data. Each bar indicates the average of three trials ± SD. B) Complement-Dependent 
Sperm Immobilization Assay. Heat-inactivated complement was used as a control. Graph depicts 
the percentage of motile sperm found in the sample compared to the total number of sperm in the 
same sample, ****p<0.0001. Black bars indicate immobilization with heat-inactivated complement 
and blue bars indicate immobilization with active human complement. Each bar indicates the 
average of three trials ± SD, in duplicate. C) Agglutination Kinetics Assay comparing 
agglutination of whole semen and washed sperm cells. “Seconds to Agglutination” is the amount 
of time taken for all the sperm in a 10x field of view to fully agglutinate. Each data point is the 
average of three trials ± SD (*p <0.05). D) Agglutination Kinetics Assay comparing agglutination 
of different washed sperm concentrations. Each data point is the average of three trials ± SD. E) 
Agglutination Kinetics Assay comparing HCA agglutination after prolonged incubation in 0.5% 
D/L lactic acid (pH 3.5) for 0, 2, 4, 24 hours. Each data point is the average of 3 trials ± SD. All 
graphs are representative of 2-3 independent experiments, and 3- 6 participant samples. 
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HCA Kinetic Activity Under Physiologically Relevant Conditions 
Washed sperm vs. whole semen 
Since soluble CD52g in seminal plasma could compete with sperm CD52g 
for antibody binding, we tested the ability of HCA to agglutinate sperm in whole 
semen versus washed sperm preparations using the Agglutination Kinetics 
Assay. At HCA concentrations >25 µg/mL, there was less than a 10 second 
difference between sperm agglutination times in whole semen compared to 
washed sperm. At lower antibody concentrations (≤12.5 μg/mL) time to 
agglutination was significantly slower in whole semen.  At 6.25 µg/mL the time 
to 100% agglutination in whole semen was 65 seconds versus 40 seconds for 
washed sperm and the time to agglutination became highly variable (Figure 
2-4C).  We also compared the ability of HCA to agglutinate sperm in whole 
semen versus washed sperm preparations using the Sperm Escape Assay (Figure 
2-4A). At HCA concentrations >12.5 µg/mL, the number of progressively motile 
sperm in the swim-up fraction was less than 5% that of media-treated sperm, 
with both whole semen and washed sperm preparations. Both assays 
demonstrate that HCA agglutinates sperm in whole semen despite the presence 
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of soluble CD52g in seminal plasma. There was no significant effect on HCA’s 
potent sperm agglutination activity at concentrations >12.5 µg/mL. 
 
Effect of sperm concentration 
In addition to soluble CD52g found in SP, agglutination time can also be 
affected by sperm concentration. Antibody-induced agglutination could be less 
efficient at low sperm concentrations because antibody-antigen interactions 
occur at a lower frequency; at higher sperm concentrations effective 
agglutination could require higher antibody concentrations. Sperm 
concentrations in human ejaculates across the population can vary from 0 
sperm/mL (azoospermia) to greater than 200x106 /mL.  Men with sperm 
concentrations ≤15 x106 /mL are oligospermic, a condition associated with 
reduced fertility302,313,314, whereas men with ≤1x106 sperm/mL are generally 
considered infertile.  We therefore tested the ability of HCA to agglutinate sperm 
over a wide range of physiological sperm concentrations.  As shown in Figure 
2-4D, HCA concentrations ≥6.25 µg/mL effectively agglutinated sperm within 
one minute at sperm concentrations between 12.5 x106 to 100x106 /mL, indicating 
that sperm concentrations within the fertile range agglutinate effectively in the 
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presence of HCA. At the lowest sperm concentration tested, 2x106 /mL, effective 
sperm agglutination occurred within 70 seconds at HCA concentrations ranging 
from 25-100 µg/mL. but took 120 seconds at the lowest HCA concentration (6.25 
µg/mL).  
 
Effect of low pH 
HCA can potentially be used as a topical product in the vaginal tract, and 
must therefore withstand low pH conditions. Vaginal secretions of reproductive-
aged women have an average pH of ~3.5 due to the production of lactic acid (LA) 
by Lactobacillus species that colonize the vagina96,97. To determine whether HCA 
can withstand low pH, we incubated HCA for 0, 2, 4, and 24 hours at 37°C in 
0.5% LA diluted in MHM. Since low pH affects sperm viability, the pH of LA-
treated HCA was neutralized to pH 7.5 by addition of seminal plasma before use 
in the kinetic agglutination assay.  While untreated HCA agglutinated sperm the 
fastest, LA-treated HCA at concentrations >12.5 µg/mL effectively agglutinated 
sperm in under one minute, and there was no significant difference across the 
various LA-treatment time points. At the lowest antibody concentration tested 
(6.25 µg/mL), sperm agglutinated in under 80 seconds and had increased 
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variability (Figure 2-4E).  These data indicate that HCA retains activity at the low 
pH conditions typically found in the human vagina. 
 
Preclinical Safety Test 
We tested the effects of HCA and HCA immune complexes in an in vitro model 
of vaginal integrity and inflammation.  Combinations of antibody, semen and 
human complement were added to the apical side of MatTek™ EpiVaginal 
tissues310 and incubated for 6 hours. After washing the apical side of the tissues 
and allowing cytokines to be secreted into fresh media for 24 hours, the apical 
and basal supernatants were collected and cytokine concentrations were 
measured by Luminex (Figure 2-5A). Our previous studies, and the literature, 
have shown that semen alone increases levels of IL-1β and IL-6 in apical and 
basal supernatants, but not HCA or complement315,316 (Figure 2-5B).  Notably, 
HCA alone and HCA in the presence of complement did not induce upregulated 
cytokine secretion in the epithelial cells when compared to the media control.  
Histology of the treated tissues showed that all tissues were morphologically 
intact after treatment with HCA/HCA immune complexes. 
  
88 
 
Figure 2-5- HCA does not increase proinflammatory cytokines in EpiVaginal tissue 
supernatants. A) Schematic of MatTek irritation assay where HCA/Semen/Complement were 
applied to the apical surface of EpiVaginal tissue. B) Left panel depicts cytokines secreted into the 
apical supernatant of tissue normalized to the media control. The right panel depicts cytokines 
secreted basally by the MatTek tissue normalized to the media control. VRC01 is an isotype 
control. Experiments were performed in duplicate. Graphs are representative of 2 individual 
experiments. 
 
Discussion  
The contraceptive revolution produced a variety of effective contraceptive 
methods and products, but a large gap remains2,7. Today, approximately 40-50% 
of pregnancies worldwide are unintended3,9,13,17. In the United States alone, 46% 
of  unintended pregnancies are due to inconsistent or incorrect use of available 
contraceptives, and  50% are due to the non-use of birth control products9. These 
numbers demonstrate the need for contraceptives that are easier to use, more 
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widely available, discreet and budget-friendly, with fewer side effects, and 
suited to diverse patient needs.  
Recent advances in the production of human mAbs have led to the 
introduction of over 70 EMA/FDA-approved mAbs for a number of clinical 
uses246,247. Our team recently completed a Phase I clinical trial in women that 
tested the safety, pharmacokinetics and ex vivo efficacy of a vaginal film, MB66, 
that released broadly neutralizing, Nicotiana-produced human anti-HIV and 
HSV-2 IgG1 mAbs for topical STI protection.  The MB66 vaginal film was found 
to be safe, and the concentration of active mAbs present in vaginal secretions 
after four hours of film insertion were sufficient to prevent HIV and HSV-2 
infection ex vivo (median >1 mg/mL)317.  With MB66 as a potential topical 
microbicide, we wanted to investigate a topical contraceptive for use with the 
anti-HIV and HSV mAbs for the potential development of an MPT. 
In this study, we have adapted an antisperm mAb, once associated with 
human infertility283, for potential use as a novel, reversible, topical contraceptive. 
We have shown that it is possible to produce a high-quality, anti-CD52g human 
IgG1, known as the Human Contraceptive Antibody (HCA), using a Nicotiana 
platform. HCA specifically targets an epitope on the N-linked glycan of CD52g, a 
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male reproductive tract specific GPI-anchored protein produced by epithelial 
cells and found on the plasma membrane of sperm. Immunofluorescence studies 
showed that HCA reacted with the head and tail of sperm, as predicted. Further 
antibody specificity was determined by a lack of reactivity of HCA with 
lymphocyte CD52 (a protein sharing the peptide sequence of CD52g but 
exhibiting distinct glycosylation); tonsil tissue, rich in lymphocyte CD52; and 
vaginal tissue. PNGaseF-treated sperm lysates, also lacked HCA detection since 
the enzyme cleaves the glycan epitope from the peptide core. The pre-clinical 
safety of HCA was also demonstrated by the conserved tissue integrity of a 
human vaginal tissue model and the absence of inflammatory cytokines secreted 
by the vaginal tissue model after prolonged topical exposure to HCA and HCA 
immune complexes. With antibodies, including IgG1, found in mucosal 
secretions as natural mediators of disease protection, we were not expecting to 
see an immunogenic response82,84,106,318,319. Altogether, these pre-clinical results 
demonstrate that HCA is specific to its intended target, suggesting safety in 
vaginal topical application. 
 The efficacy and potency of HCA under a variety of physiologically 
relevant conditions were demonstrated by sperm agglutination and swim-up 
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studies. HCA at the highest concentration tested (100 µg/mL) agglutinated 100% 
of sperm within 20 seconds. At concentrations > 6.25 µg/mL, HCA consistently 
agglutinated sperm in whole semen and washed sperm preparations in less than 
60 seconds. Effective agglutination was additionally observed across a wide 
range of sperm concentrations (2 x106 to 200x106 /mL), and Figure 2-3D reiterated 
that mAb concentrations, rather than sperm concentration, determines “Time to 
Agglutination”. HCA also continued to agglutinate effectively after prolonged 
exposure to LA pH 3.5, a condition generally found in the human vagina. The 
modified swim-up Sperm Escape Assay reflected similar efficacy. Fewer than 3% 
of individual progressively motile sperm, when compared to the media control, 
were detected in sperm preparations after treatment with HCA at concentrations 
>6.25 µg/mL. Complement- mediated sperm immobilization was also observed 
at extremely low HCA concentrations (> 0.78 µg/mL) suggesting an additional 
sperm-inhibiting mechanism in mucosal tissues. While not in the scope of this 
study, HCA has the potential to interact with vaginal mucins and hence mucus-
trap sperm that escape agglutination.  Altogether, these data on HCA potency 
are promising and demonstrate the feasibility of topical application of HCA for 
contraception.  
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HCA is a highly effective contraceptive antibody that could address some 
of the current gaps in the contraception field6,35,36,40,320, however costs and delivery 
methods need to be kept in mind. One of the limitations of antibody 
therapeutics, is their high cost9. Nevertheless, new production platforms such as 
Nicotiana, second generation CHO, and fungus are projected to bring the cost of 
mAbs down to approximately $10/gram, thereby making it feasible to use mAbs 
for contraception and MPT applications. Bispecific and multivalent monoclonal 
antibodies are also currently being engineered to have even greater potency321, 
which could bring the cost down further as less product will likely be needed to 
reach clinical effectivity. Due to the potential low cost of the mAb and its safety 
profile, HCA as a topical contraceptive could be accessible to patient populations 
worldwide, overcoming a limitation with current contraceptives322–324.   
This study does not address delivery methods for a topical contraceptive. 
HCA administered via film, if pharmacokinetically similar to MB66, can 
maintain contraceptive concentrations for up to 24 hours (MB66 median= 32.2 
µg/mL). Vaginal films are considered an “on-demand” product. For a long acting 
reversible contraceptive, a common request for contraceptive products, HCA can 
be administered with an intravaginal ring (IVR). End-product user’s needs must 
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be kept in mind during product delivery development for HCA to fully address 
the contraceptive gap.  
Finally, one of the most attractive components of HCA is its potential to be 
combined with other antibodies or small molecules, without altering its 
efficiency. The condom, currently, is the only product on the market offering 
both contraception and STI protection. HCA’s ability to work in tandem with 
other molecules, such as MB66 antibodies, opens the door to a topical, non-
barrier multipurpose prevention technology, a currently unaddressed global 
need. 264–267.  
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Chapter 3 - HCA as a candidate for microbicide protection 
Introduction 
This chapter investigates HCA as a topical microbicide to prevent male-to-
female sexual transmission of CD52g+ Trichomonas vaginalis and HIV-1.  
Trichomonas vaginalis has a plasma membrane composed of a phospholipid 
bilayer, akin to sperm and seminal cells that readily take up GPI-anchored 
CD52g, the target for HCA. The recent sequencing of Trichomonas vaginalis’ 
genome demonstrated expression of proteins needed for ceramide 
phosphoinositol (CPI) anchor biosynthesis, but not for GPI-anchor biosynthesis, 
explaining the documented absence of GPI-anchored proteins in TV237,329–331. 
However, the absence of GPI-anchored surface proteins on TV, which are 
otherwise found in protozoa329, does not suggest that exogenous GPI-anchored 
CD52g cannot embed in the TV’s plasma membrane. Similarly, HIV-1 is a virus 
obtaining its envelope from the plasma membrane of its CD4+ host cell. GPI-
anchored proteins have been shown to insert into enveloped viruses, either 
through 1) budding from host cells since GPI-anchored proteins are known to 
accumulate at sites of viral budding (Figure 3-1) or 2) by direct embedding of 
soluble GPI-anchored proteins into the viral envelope, a process termed 
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“painting”202,277,332. We hypothesize that these CD52g+ virions and parasites can 
be targeted by HCA, leading to agglutination, inactivation, and/or elimination.  
To determine if HCA can potentially prevent the sexual transmission of 
HIV-1 and Trichomonas vaginalis, we first determined whether CD52g can coat 
these pathogens. Trichomonas vaginalis was incubated with seminal plasma 
(containing soluble CD52g), and the resulting CD52g coating of the pathogen 
was verified with immunofluorescence and western blot. HCA agglutination of 
CD52g+ TV was investigated using the CASA and a modified version of the 
swim-up assay described in Chapter 2. TV adhere to vaginal epithelial cells upon 
infection. HCA’s role in preventing TV’s adherence to its target cells was studied 
using MatTek™ EpiVaginal tissue and VK2/E6E7 epithelial cell models. HIV-1 
virions were coated with CD52g by budding from SP-treated, CD52g+ HEK293T 
cells and by viral painting with SP. Coating was verified with “antibody capture 
plates” and colloidal gold staining and transmission electron microscopy. HCA 
agglutination of CD52g+ virions with sperm was determined by p24 
concentrations found in virus-sperm supernatants. HCA neutralization of HIV-1 
was evaluated by modifying Montefiori’s TZM-bl neutralization assay333.  
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Figure 3-1- Schematic depicting GPI-anchor hypermobility in painting and budding 
incorporation in enveloped viruses. Painting was used for TV, and budding for HIV. Figure 
adapted from Dangerfield 2008. 
 
Methods 
Antibodies 
The human anti-CD52g mAb, HCA, the human broadly neutralizing mAb, 
VRC01-N, and MB66 film (containing VRC01-N and HSV8) were produced by 
Mapp Biopharmaceutical Inc. (San Diego, CA, USA) in Nicotiana benthamiana, as 
described in Chapter 2.  
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Trichomonas vaginalis Experiments 
Trichomonas vaginalis culture method 
T. vaginalis were cultured in TYM broth supplemented with 10% FBS and 1% 
Pen/Step, 1x dilution of Diamonds Vitamin Tween 80 solution 40x (58980C, 
Millipore Sigma, Burlington, MA, USA) and grown in a polystyrene flat bottom 
10 mL culture tube with a screw cap (62407-076, VWR, Radnor, PA, USA). T. 
vaginalis were passaged every 48 hours with a 1:1000 dilution; they were 
incubated at 37 °C under anaerobic conditions.  
 
Trichomonas vaginalis CD52g “painting” 
Trichomonas vaginalis were incubated 5-7x10^6 in 5 mL of pooled seminal plasma 
or media (negative control) with a 1x dilution of Diamonds Vitamin Tween 80 
solution for 2 hours at 37℃. Protozoa were washed twice in PBS. Washed T. 
vaginalis were then resuspended in media. 
 
VK2/E6E7 cell culture 
Vaginal epithelial cells, VK2/E6E7 were cultured according to ATCC’s 
instructions in Keratinocyte-Serum Free medium (17005-042, ThermoFisher 
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Scientific, Waltham, MA, USA). The media includes 0.1 ng/mL human 
recombinant EGF, 0.05 mg/mL bovine pituitary extract. Additional calcium 
chloride was added per ATCC instructions (final concentration, 0.4mM). VK2 
were trypsinized and neutralized with complete RPMI (10% FBS, 1% Pen/Strep, 
1% L-glutamine), spun and plated for passage.  
 
EpiVaginal culture 
EpiVaginal™ tissues were acclimated for at least 24 hours post-delivery at 37°C, 
5% CO2, and cultured according to the manufacturer’s instructions (VEC-100-FT, 
MatTek Corporation, Ashland, MA, USA). Transepithelial resistance (TEER) 
assessments were performed to confirm tissue integrity. Only tissues with TEER 
values higher than 400 ohms were used.  Media was replaced an hour before 
performing adherence assays. 
 
Immunofluorescence 
Trichomonas vaginalis were incubated in CMFDA (1:500 dilution) for 20 minutes 
at RT before CD52g painting. TV were resuspended in PBS, air dried and 
subsequently fixed in methanol or acetone. Samples were rehydrated in 1x TBS, 
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blocked, and stained with 100 μg/mL of primary antibody for 1 hour at RT. 
Secondary was diluted 1:200 and incubated with samples at RT for 1 hour. 
Coverslips were mounted with DAPI-containing mounting medium. HCA was 
used to detect CD52g and VRC01-N was used as an isotype control.  
 
SDS-PAGE 
Painted TV were washed in PBS and resuspended in RIPA buffer with 0.5% 
Sodium Orthovandate, 0.5% PMSF in DMSO, and 1% protease inhibitor cocktail 
(sc-24948, Santa Cruz Biotechnology, Inc. Dallas, TX, USA). Lysed sample was 
freeze-thawed before spinning out cell debris at 400g at RT. Protein 
concentration of the lysed sample was determined via bicinchoninic acid assay 
(BCA) (23227, Thermo Scientific, Waltham, MA). SDS-PAGE was run with 10-20 
μg of sample lysis loaded onto a 4-12% gradient gel (4561084, Bio-Rad, Hercules, 
CA, USA) in commercial running buffer (1610732, Bio-Rad). 
 
Western blot 
The gel was transferred to a PVDF membrane with commercial transfer buffer 
(1610734, Bio-Rad). The blot was blocked in 5% dry milk overnight, and 
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incubated in 10 μg/mL of primary HCA in BSA. HRP-conjugated anti-human 
secondary was diluted 1:2000. The membrane was stripped and activated with 
methanol prior to Ponceau staining (59803, Cell Signaling Technology, Danvers, 
MA, USA). 
 
Agglutination studies 
Direct agglutination.  
 Trichomonas vaginalis were painted with CD52g from SP as described above. 
Cells were washed twice in T. vaginalis media. The CASA was modified to detect 
Trichomonas vaginalis by modifying light and progressive/motile settings. The TV 
agglutination assay is performed similarly to the Sperm Escape Assay. Briefly, 
mAbs were diluted in TYM media and 30 μl were added to 0.2 mL PCR tubes. 
Thirty μL of sample were then added to the mAbs and mixed three times by 
pipetting; the mixed sample was placed at a 45° angle. A 3 μL sample was taken 
from the top of the PCR tube and placed in a 4-chambered slide after a 5-minute 
incubation at RT. The CASA was used to count T. vaginalis. 
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Trichomonas vaginalis co-agglutination 
TV were painted with SP as described above. Protozoa were washed twice in 
MHM. Pelleted T. vaginalis were resuspended in either whole semen or washed 
sperm cells. MAbs were diluted in MHM and 30 μL were added to 0.2 mL PCR 
tubes. Thirty μL of co-cultured sample were added to the mAbs and mixed three 
times by pipetting; the PCR tube was then placed at a 45° angle and incubated 
for 5 minutes at RT. A 3 μL sample was taken from the top of the sample, placed 
in a 4-chambered slide, and analyzed by CASA.  
 
Adherence studies 
Two different tissue culture models were used for adherence models: MatTek 
EpiVaginal Tissue and VK2/E6E7 cells.  
For the EpiVaginal MatTek tissue assay, Trichomonas vaginalis were painted with 
seminal plasma, stained with CMFDA (1:500 dilution), and washed and 
resuspended in serum-free MatTek tissue media. Washed sperm cells and 
antibody were also resuspended in serum-free MatTek tissue media.  Antibody 
was placed on the apical side of MatTek tissue and incubated for 1 hour before 
removal. Sperm and TV were then added and allowed to incubate for 1 hour at 
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37°C. The apical side of the tissue was washed 3x with warmed PBS and the 
tissues were fixed with formaldehyde at 4°C, overnight. The tissues were then 
placed apical side down in DAPI mounting media in glass bottom plates 
(P35GC-1.5-10-C, MatTek Corporation, Ashland, MA, USA).  Tissue was imaged 
using a Leica SP5 confocal microscope (Training and access courtesy of Cellular 
Imaging Core, Boston University School of Medicine). 
 
The VK2 epithelial cell model was prepared 24 hours before running the assay. 
Coverslips were used to grow the VK2 monolayer. A hydrophobic pen (S200230-
2, Dako Agilent, Santa Clara, CA, USA) was used to draw four rectangular wells 
on the cover slips. A piece of tape (for labeling) was affixed to 0.5 cm of the 
coverslip (Figure 3-2). The coverslips were sterilized with UV light in a cell 
culture hood for 1 hour. VK2 cells were trypsinized, neutralized with complete 
RPMI, and resuspended in their media after washing. Cells were seeded at 
125,000 cells per well and allowed to adhere overnight; media was replaced the 
following morning. All cells and antibodies were resuspended or diluted in the 
Keratinocyte Serum-Free Media. T. vaginalis adherence was determined as 
described above for MatTek tissue with the exception that HCA was not washed 
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off the monolayers. T. vaginalis was allowed to adhere for an hour at 37 °C. 
Coverslips were gently washed with PBS and fixed with acetone. Samples were 
rehydrated in 1x TBS for 5 minutes before mounting in DAPI mounting media 
onto a glass slide. 
 
Figure 3-2- Schematic of customized coverslip wells for VK2 monolayer culture. Green 
represents hydrophobic pen demarcations 
 
HIV-1 Experiments 
CEM cell culture 
CEMs, a T cell line were cultured in complete RPMI. Passages were maintained 
at 300,000 cells/mL. Cells were activated at 1x10^6 with 10 μg/mL of PHA (00-
4977-03, ThermoFisher Scientific, Waltham, MA, USA) for 48 hours before HIV-1 
infection. 
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PBMC cell culture 
Peripheral Blood Mononuclear Cells (PBMCs) were acquired from blood packs 
provided by healthy donors (NYBiologics, Southampton, NY, USA) and isolated 
with Ficoll (17144002, GE Healthcare Life Science, Marlborough, MA, USA). Cells 
were stored at -80C until use. Frozen stocks were thawed and washed with 
complete RPMI at 50x the frozen stock volume. Cells were activated upon 
thawing for 48 hours and allowed to rest for 24-48 hours.  
HEK293T cell culture 
An aliquot of HEK293T was generously provided by the Henderson lab. Cells 
were cultured in High Glucose Dulbecco’s Modified Eagle’s Media 
supplemented with 10% FBS, 1% Pen/Strep, and 1% L-Glutamate. 
HIV-1 strains 
The following strains of HIV-1 were used for these studies. Plasmids or viral 
supernatants were generously provided by Luis Agosto, Ph.D. and the AIDS 
Reagents Program. This work was facilitated by the Providence/Boston Center 
for AIDS Research (P30AI042853). 
 NL43-IRES-GFP-nef+ 
 NL43-GAG-eGFP 
 Q23-17 
 TRJO 
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HIV-1 CD52g “painting” 
Virus was pulsed with pooled healthy SP or media for 3 hours on a shaker at 
37℃.  
 
HEK293T transfection 
HEK293T cells were passaged once, at a minimum, after thawing before being 
used for transfection and were not kept for more than 5 weeks. Cells were plated 
at 0.5x10^6 cells approximately 24 hours before transfection. Media was replaced 
8 hours before transfection. HIV-1 DNA plasmid was prepared with PEI in a 3:1 
ratio.  At 22 hours post transfection, HEK293T cells were pulsed for 2 hours with 
SP. Adherent cells were washed with warm 1x PBS and non-adherent cells were 
spun out of SP, washed once, and re-plated. Viral supernatant was collected 40 
hours post transfection. 
 
CEM infection with Q23-17 and SP pulsation 
In a 96 well plate, 300,000 cells per well were plated and spinoculated with Q23-
17 virus for 2 hours at 1200g at RT. Spinoculated cultures were incubated for 30 
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minutes at 37 ℃. Cells were washed in cold 5% FBS in PBS and re-plated at 
10,000 cells/well in warm complete RPMI.  
 
PBMC infection with TRJO 
PBMCs were activated with 10 μg/mL of PHA and 20 μg/mL of IL-2 for 48 hours. 
Cells were placed in IL-2 supplemented media for 24-48 hours before infection. 
Cells were infected at a concentration of 1x10^6 cells/mL in 500 μL in DEAE 
supplemented media. Cells were washed at RT with 5% FBS in PBS before being 
placed into culture. Cells were incubated at 37 ℃ for 4 hours and cells were 
resuspended every hour. 
 
PBMC infection for immunogold Transmission Electron Microscopy (TEM) 
PBMCs were activated with PHA and IL-2 as described above. Cells were pulsed 
with SP at 36 hours post-infection for 2 hours, washed 2x, and allowed to 
incubate for 4 hours before staining. Cells were centrifuged at 300g, and, on ice: 
blocked with FcR block for 30 minutes (NB309, Innovex Biosciences, Richmond, 
CA, USA), blocked with 5% FBS in PBS for 30 minutes; reacted with HCA for 60 
minutes, and washed twice with 10% FBS before adding colloidal gold-
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conjugated anti-human IgG secondary (109-205-088 and 109-195-088, Jackson 
ImmunoResearch Laboratories, Inc, West Grove, PA) at a 1:20 dilution per 
manufacturer’s instructions.  Following a 60 minute incubation in secondary 
antibody, cells were washed in PBS, fixed in 2.5% Paraformaldehyde, 5.0% 
glutaraldehyde, 0.06% picric acid in 0.2 M cacodylate buffer, and further 
processed (embedded, sectioned and visualized) by the Harvard Imaging Core.  
 
Immunofluorescence 
Cells were transfected or infected with a GFP-labelled HIV-1 and were air-dried 
on slides and fixed in acetone. Samples were rehydrated in 1x TBS, blocked and 
stained with 1) Cy3-conjugated HCA and HSV8 for 3 hours at room temperature 
or 2) unconjugated primary antibody incubated for 1 hour at RT, washed, and 
stained with Cy-3 conjugated anti-human IgG secondary. Samples were 
mounted with DAPI-containing mounting medium. HCA was used to detect 
CD52g, and the HSV8 mAb was used as an isotype control.  
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Viral plate capture 
Non-tissue-treated 96-well plates (351172, Falcon, NYC, NY, USA) were coated 
with antibody diluted in PBS and serially diluted 2-fold. Plates were incubated at 
37 °C overnight. Plates were washed with PBS before blocking with 5% FBS in 
PBS for 1 hour at 37 °C. Blocked plates were washed with 1x PBS before adding 
virus sample. Virus supernatant was allowed to incubate with plate-bound 
antibodies for 3 hours at 37°C before being transferred to p24 ELISA plates to 
quantify unadhered virus. 
 
HIV-1/Sperm cell co-culture 
Virus was added to washed sperm cells and aliquots of the cell suspension were 
added to serially diluted antibody in MHM. The antibody/virus/sperm mixture 
was allowed to incubate for 10 minutes at RT before being gently spun down at 
300g for 5 minutes at RT to pellet cells. The supernatant was removed and 
uncaptured virions still in suspension were quantified by p24 ELISA. 
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p24 ELISAs 
Non-tissue culture treated 96-well plates were coated with 20 µg/mL of HIV-1 
polyclonal antibody (3957, NIH AIDS Reagent Program) diluted in PBS and 
incubated at 37°C overnight. Plates were washed with PBS prior to blocking in 
Blocking Buffer (5% FBS in 1xPBS) for 1 hour at 37 °C. The samples tested were 
diluted 1:1 with sample diluent (10%FBS, 0.5% Triton-X in PBS) and added to 
capture antibody for 2 hours at 37 °C. Anti-p24 primary detection antibody (183-
H12-5C, NIH AIDS Reagent Program) was diluted in sample diluent and 
incubated for 1 hour at 37 °C. HRP-conjugated anti-mouse IgG secondary 
antibody was treated similarly (sc-2005, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA). Plates were washed 3x with wash buffer (0.2% Tween in PBS) 
between each of these steps. 1X TMB was added to the plate and incubated at RT 
until the lowest concentration of the standard turned a pale blue. Reaction was 
neutralized with 4M Sulfuric Acid (S25898, Fisher Scientific, Hampton, NH, 
USA).  
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Neutralization assays with TZM-bl cells 
HIV-1 neutralization assays 
Antibody and virus were diluted to desired concentrations in complete DMEM 
media. Antibody and virus were incubated for 30 minutes at RT in a clear 
bottom, black 96-well plate (3603, Fisher Scientific, Hampton, NH, USA). 10,000 
TZM-bl cells, suspended in DMEM with 20 µg/mL of DEAE, were added to each 
well. TZM-bl cells were infected with virus for 46-48 hours before lysis. 
Galactosidase production (a measure of HIV infection) was assessed with a 
chemiluminescent kit following manufacturer’s instructions (T1011, 
ThermoFisher Scientific, Waltham, MA, USA)333. 
 
HIV-1/Sperm neutralization assays 
TZM-bl cells were plated at 10,000 cells/well 16 hours before infection. Media 
was replaced the following morning with 20 µg/mL of DEAE added. Antibody 
was diluted in tissue culture-treated v-bottom, 96-well plates (3894, Corning, 
Corning, NY, USA). Previously titrated HIV-1 was added to washed sperm cells 
or media (negative control); the mixture was then added to the antibody 
dilutions, and transferred to the plated TZM-bls. For HCA-VRC01 antibody 
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concentration, VRC01 was serially diluted, while HCA was kept at a 
concentration of 50 µg/mL. Virus and cells were incubated overnight before 
being replaced with fresh DMEM. TZM-bl cells were lysed 46-48 hours post-
infection and read with a chemiluminescent kit  
Semen Analysis and Sperm Preparation 
Healthy men, between 18-45 years old with sperm samples meeting the WHO’s 
semen characteristics for fertility, provided the samples for this study as 
approved by the Boston University Medical Campus Institutional Review Board. 
Participants provided written informed consent for the study.   
Samples were processed within one hour of collection. For Trichomonas vaginalis 
studies, live sperm were separated by passage through 90% ISolate density 
gradient medium (FUJIFILM Irvine Scientific; Santa Ana, CA, USA) as described 
in Chapter 2. For HIV-1 co-culture studies, sperm were pelleted from seminal 
plasma by centrifugation at 350g for 20 minutes at room temperature (RT). Cells 
were resuspended in assay medium, and sperm count and motility were 
assessed by CASA. 
  
112 
Statistical Analysis 
GraphPad Prism (Version 7.03; GraphPad Software Inc.; San Diego, CA, USA) 
was used for statistical analysis and graphing. Data were subjected to analysis of 
variance (ANOVA).  A significant ANOVA was followed by post hoc multiple 
comparison tests as recommended by software settings. Differences were 
considered to be statistically significant when p-value<0.05.   
 
Results 
CD52g Coats the Surface of Trichomonas vaginalis 
To determine the effect of HCA on Trichomonas vaginalis, we first had to 
determine whether CD52g inserted onto the plasma membrane of the protozoa. 
This was determined by immunofluorescence (IF) and western blot assays. While 
flow cytometry was attempted, TV did not survive the staining, and fixing cells 
before staining led to conflicting results (data not shown). Immunofluorescence 
of pulsed TV is shown in Figure 3-3A. DAPI was used to stain protozoal nuclei. 
CMFDA is a green cytoplasmic dye which requires enzymatic activity in the 
cytosol, hence staining live cells. CD52g was detected with HCA primary and 
Cy3-conjugated secondary antibodies. VRC01, an HIV-1 gp120 specific antibody, 
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was used as an isotype control. As shown in Figure 3-3, following incubation in 
seminal plasma, TV were painted with CD52g and detected with  HCA antibody. 
Trichomonas vaginalis incubated for 2 hours in fresh TYM media and SP-treated 
TV stained with VRC01 (negative control), were not positive in the 
immunofluorescence assay.  
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Figure 3-3- HCA coats the plasma membrane of Trichomonas vaginalis. A) 
Immunofluorescence of Trichomonas vaginalis pulsed for 2 hours in SP (CD52g+, red) or media 
(CD52g-). CMFDA (green) is a cytoplasmic stain. DAPI nuclear stain is blue. VRC01 was used as 
an isotype control. Red arrow indicated CD52g band. All images at 20x magnification. B) Top 
panel is a Ponceau staining of PVDF membrane of Western blot (bottom panel) of pulsed and 
lysed Trichomonas vaginalis. VRC01 was used as an isotype control.  
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Western blot was used to confirm the presence of CD52g in SP-treated 
protozoa. Painted TV were washed in PBS three times before being lysed for 
western blot, to thoroughly remove SP. Figure 3-3B (bottom panel) depicts a ~25 
kDa band, highlighted with a red arrow. The band is the expected size of 
denatured CD52g. As shown in the western blot panel of Figure 3-3B, only SP 
(containing soluble CD52g) and SP treated TV had a ~25 kDa band when blotted 
with HCA primary. Media-treated TV reacted with HCA and VRC01-N blotted 
membranes (an isotype control) did not show 25 kDa CD52g band. Commercial 
antibodies for TV were not suitable for western blot and typical loading controls 
(such as actin) were found to be ineffective for TV western blotting. Therefore, 
Ponceu stain, a negatively charged red dye that reacts with positively charged 
amino acids, was used to confirm protein loading on our PVDF membrane prior 
to blotting (figure B, top panel).  
HCA Agglutinates CD52g+ Trichomonas vaginalis in Whole Semen 
After CD52g insertion was determined, HCA’s ability to agglutinate 
Trichomonas vaginalis was evaluated using a modified version of the swim-up 
assay. The CASA was modified to detect individual protozoa (Figure 3-4A). TV 
motility could not be reliably evaluated by the CASA due to software constraints 
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specific to sperm, such as cross beating frequency, which relies on sperm head 
and flagella movement. However, altering the parameters on specimen size and 
light reflection enabled the CASA to detect individual and agglutinated 
Trichomonas vaginalis and correctly distinguish them from sperm cells, as shown 
in Figure 3-4B.  
 
Figure 3-4-CASA settings for Trichomonas vaginalis detection. A) Detection setting for TV. B) 
CASA image showing Trichomonas vaginalis detection by CASA (represented by red dots on the 
protozoa) while excluding sperm at 10x magnification. 
 
  
117 
The use of the CASA permitted the implementation of a modified “sperm 
escape assay”, as shown in Figure 2-4. Unlike sperm cells, Trichomonas vaginalis 
did not agglutinate in the presence of HCA even when painted with CD52g 
(Figure 3-5A). Agglutination was assessed at a variety of TV concentrations, 
prolonged incubation with antibody and even gentle spinning to encourage 
protozoal/antibody interactions (Data not shown). We next co-agglutinated 
Trichomonas vaginalis in the presence of washed sperm and whole semen. As 
shown in Figure 3-5B, there were fewer free-swimming CD52g+ TV in co-
cultured samples upon HCA treatment. A dose response was observed with a 
~50% reduction of free TV (compared to media control) observed at 100 µg/mL 
and only a ~30% reduction found at 6.25 µg/mL. To a lesser degree, a modest 
dose response was also found with free swimming CD52g- Trichomonas vaginalis, 
but was not statistically significant. The decrease of CD52g+ TV in sample taken 
from HCA treated co-cultures was more pronounced when whole semen 
samples were used in co-agglutination. Fewer CD52g- TV were also found at 
higher HCA concentrations in TV-Semen co-culture samples(Figure 3-5C).  These 
data suggest that co-agglutination with sperm could play a role in hindering 
Trichomonas mobility in the presence of HCA. 
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Figure 3-5- Trichomonas vaginalis agglutination alone, with sperm cells, and whole semen. A) 
T. vaginalis escape assay with SP pulsed and media pulsed T. vaginalis. B) T. vaginalis escape assay 
with both SP pulsed and media pulsed T. vaginalis agglutinated with washed sperm. C) SP and 
media pulsed T. vaginalis escape assay with whole semen. Black bars indicate media pulsed 
(CD52g-) Trichomonas vaginalis. *p-value<0.05, **p-value<0.01. Red bars indicate SP pulsed 
(CD52g+) Trichomonas vaginalis. Graphs are each representative of three experiments. 
 
HCA Blocks Adherence of TV to Vaginal Epithelial Cells 
Trichomonas vaginalis infection occurs when the protozoa adhere to 
epithelial cells in the FRT. Adherence studies were done both in MatTek 
Epivaginal tissue and VK2 cells. Figure 3-6 shows the MatTek tissue results. 
Trichomonas vaginalis were treated with CMFDA and painted with SP as 
described above. The protozoa were subsequently added to the apical side of the 
tissue, with or without sperm, and with or without HCA pre-treatment. The cells 
were allowed to adhere to the tissue for an hour; the tissue was gently washed to 
remove any unattached TV. The apical side of the tissue was then imaged, and 
the individual fluorescent TV were manually counted in each field of view. 
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Manual counting was preferred since the amoeboid form of adhered Trichomonas 
sp. exhibited variable particle size and was not easily quantified by ImageJ. As 
shown in  Figure 3-6A, fewer SP-treated Trichomonas vaginalis adhered to the 
epithelial cells than media-treated TV. TV adherence was unaffected by the 
presence of HCA or sperm alone in the tissue model.  Interestingly, decreased 
pathogen adherence was found in CD52g- TV in the combined presence of HCA 
and sperm. Washed sperm, not whole semen, was used since the presence of 
semen was found to prevent Trichomonas adherence (data not shown) in vitro.  
Due to the lower adherence found in SP-treated TV, the assay was insufficiently 
powered to detect significance; nevertheless, like CD52g- TV, CD52g+ TV 
adherence was reduced in sperm co-culture in HCA-treated tissue. Adherence 
was also studied with a confluent VK2 monolayer grown on a coverslip. 
Quantification with VK2s was facilitated with ImageJ, since VK2 and TV nuclei 
were visibly different sizes allowing TV nuclei to be consistently counted. HCA, 
unlike in the MatTek tissue model, was not washed off after an hour incubation 
since there was no evidence for antibody uptake in the cell monolayer (data not 
shown). In VK2 monolayers, unlike MatTek tissues, there was a significant 
decrease in adherence for (Figure 3-6B) both CD52g+ and CD52g- TV in the 
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presence of the antibody alone. Like in the MatTek adherence assay, CD52g+ TV 
adherence was reduced. Similarly, the decreased TV adherence in the combined 
presence of HCA and SC was reflected in both CD52g+ and CD52g- TV.  
 
Figure 3-6-Trichomonas vaginalis adherence assays. A) T. vaginalis adherence assays with 
MatTek tissue. TV-= T. vaginalis pulsed in media; TV+= T. vaginalis pulsed in SP. Graph is 
representative of n=2 experiments. B) T. vaginalis adherence assay on VK2 monolayer. Black bars 
indicate media pulsed (CD52g-) Trichomonas vaginalis. Red bars indicate SP pulsed (CD52g+) 
Trichomonas vaginalis. ****p-value<0.0001; ***p-value<0.0005; **p-value<0.005, *p-value<0.05. 
Graph is representative of n=2 experiments. 
 
Producing CD52g+ HIV-1 Virions 
HIV has a phospholipid envelope thereby enabling the incorporation of 
GPI-anchored CD52g possible. To determine whether HIV-1 picks up CD52g 
during budding from CD52g-coated host cells (e.g. HIV-infected cells in the male 
genital tract and semen), we transfected NL43-IRES-GFP-nef+ and NL43-GAG-
eGFP virus plasmid into SP-treated HEK293T cells. Twenty-four hours post-
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transfection, HEK293Ts were pulsed with seminal plasma. Cells reacted poorly 
to SP treatment, lifting off within an hour pulsation (data not shown). Unadhered 
cells were spun out of the SP and washed before being reintroduced into culture; 
HEK293T cells survived seminal plasma treatment and re-adhered; however, SP 
pulsation did decrease HIV-1 production, and higher volumes of virus were 
needed to obtain levels of infection similar to those of media controls. Flow 
cytometry was then used to determine transfection efficiency. As shown in 
Figure 3-8, SP-treatment caused background in flow cytometry. If the 12.9% 
background is disregarded, the transfection efficiency is ~50% in SP-treated 
NL43-GAG-eGFP transfected cells versus a rate of 60% transfection found in 
media-treated cells. The decreased transfection efficiency is also readily apparent 
by immunofluorescence in the decreased number of HEK293Ts with GFP-tagged 
HIV-1 (Figure 3-7). HEK293T cells were still coated in CD52g (detected with 
HCA primary and Cy3 secondary) at the time of virus harvest as shown in 
Figure 3-7; CD52g was only detected on SP-pulsed HEK293T cells.  
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Figure 3-7-HCA coats the plasma membrane of transfected HEK293T cells. A) 
Immunofluorescence of HEK293T cells pulsed for 2 hours in SP (CD52g+, red) or Media (CD52g-
). Green Fluorescence indicates GFP-tagged GAG protein of HIV-1. DAPI nuclear stain is in blue. 
VRC01 was used as an isotype control. All images were at 20x magnification. 
 
  
123 
 
Figure 3-8-Transfection efficiency of SP pulsed HEK293T cells compared to media controls. 
GFP tagged virus (NL43-GAG-eGFP) allowed easy detection of transfection of HEK293T cells. 
PEI-SP pulsed mock transfected cells were included to show background induced by SP.  
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Confirming CD52g on HIV-1 Envelope 
While troubleshooting virus production, it was necessary to come up with 
a proxy measure for testing the presence of CD52g on the HIV-1 envelope. We 
therefore coated plates, referred to as “capture plates” with either HCA, HSV8 
(an isotype-matched negative control antibody), or VRC01 (an isotype-matched 
positive control antibody specific for gp120 on HIV-1). The supernatant from the 
antibody capture plates was subsequently quantified with a p24 ELISA. If the 
virus was captured by the immobilized antibody on the plate, less virus would 
be found in the supernatant. As shown in Figure 3-9A and B, p24 found in the 
viral supernatant was significantly decreased with CD52g+ virus captured by 
VRC01 and HCA (p-value< 0.00005), but not with HSV8. For CD52g- virus, a p24 
decrease was only found in the supernatant incubated with immobilized VRC01 
(p-value<0.05), suggesting that CD52g does coat the surface of HIV-1 virions 
produced from SP-treated HEK293T cells. There was no significant dose 
response found for each antibody so only the 25 µg/mL data is shown. A western 
blot was also run on concentrated virus, and CD52g was readily detected in 
lysates from the SP-pulsed virus (Figure 3-9C).  
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Figure 3-9-Proxy measures for CD52g detection. Capture plate supernatant quantified with p24 
ELISA assay from A) virus made with SP-treated HEK293T and B) media-treated HEK2913T.  
Graphs are representative of three experiments. C) Western blot of concentrated SP-pulsed HIV-
1. CD52g was detected with HCA. *p-value<0.05, ***p-value<0.00005 
 
CD52g+ HIV-1 Production with T cells 
HEK293T cell transfection is the preferred method for virus production in 
the lab, but we also wanted to confirm that PBMCs could be coated with CD52g 
and produce virus, as this would likely be a mechanism of CD52g virion coating 
in the MRT. We ran a time course to determine how long CD52g protein 
  
126 
remained on the plasma membrane of SP-pulsed T cells (CEM data shown). SP-
pulsed cells were washed and cultured in complete RPMI. At specific time 
points, cells were fixed and either plated for IF or saved for flow cytometry. As 
shown in Figure 3-10, cells retained CD52g, detected with directly conjugated 
Cy3 HCA, for up to 8 hours post-SP treatment (Panel A). Flow cytometry 
showed similar results, although positive CD52g staining was found at 24 hours 
(Figure 3-10C).  
Infected CD52g+ PBMCs were prepared for TEM in order to determine if 
CD52g could be found on HIV-1 transmitter-founder virions. Cells were infected 
before incubation in SP, since data showed that SP pulsation during infection 
delayed virus production for 24 hours (data not shown). Infected cells were used 
for TEM instead of free virus to facilitate staining and imaging.  TEM images of 
CD52g+ infected PBMCs are shown in Figure 3-10. Panel D shows positive 
staining of CD52g+ sperm with arrows demonstrating 12 nm colloidal gold 
staining, a positive control. Panel B and D show colloidal-gold staining of virions 
and empty vesicles, respectively. However, the plasma membrane of the PBMCs 
had little labelling and only a few HIV-1 virions were labelled. While 
preliminary TEM images suggest that CD52g is found on the surface of the HIV-
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1, colloidal gold labeling needs to be improved to detect CD52g on the plasma 
membrane of PBMCs in order to confirm the result. 
 
Figure 3-10- CD52g coats T cells and is detectable on the envelope of virions and vesicles. A) 
Immunofluorescence of CEMs 8 hours post-SP pulse and B) 48 hours post-SP pulse. 20x 
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magnification. Cy3 staining indicates presence of CD52g. C) Flow cytometry of CD52g on CEMs 
fixed at different time points Post-SP pulse. D) TEM of CD52g+ sperm, T cells, and TRJO virus at 
25,000x magnification. Virus particles zoomed in for visualization. Red arrows point to colloidal 
gold 12nm. 
 
HIV-1 Co-agglutinates with Sperm When Treated with HCA 
Once CD52g coating had been ascertained, we determined whether HCA could 
neutralize CD52g-coated virus. As shown in Figure 3-11A, both CD52g+ virus 
and CD52g- virus were neutralized by VRC01 in the TZM-bl assay, but not by 
HCA or HSV8 (isotype control). To determine whether HIV-1 co-agglutinates 
with sperm in the presence of HCA (similar to TV), CD52g+ and CD52g- HIV 
was mixed with sperm and treated with VRC01, HCA, and HSV8 in an 
experimental set-up similar to the “sperm escape assay” and the TV co-
agglutination assay. The sperm were gently spun down and the free HIV-1 in 
supernatant was quantified with a p24 ELISA. If the virus was captured by the 
antibody or co-agglutinated with sperm cells, then less p24 should be found in 
the supernatant. As shown in Figure 3-11B and C, both VRC01 and HCA treated 
co-cultures have decreased p24 in the co-culture supernatant when compared to 
HSV8. This trend was found whether or not the virus was coated with CD52g. 
The decreased p24 values in VRC01 treated cultures, while unexpected, are likely 
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due to the fact that p24 ELISA plates are coated with an HIV-1 polyclonal 
antibodies and VRC01 antibody decreased HIV-1 capture hence decreasing p24 
values. Again, no significant dose response was observed so only the data from 
25 µg/mL are shown. 
 
  
Figure 3-11-HCA does not neutralize virus but co-agglutinates HIV-1 in the presence of sperm. 
A) CD52g+ and CD52g- NL43-IRES-GFP virus was neutralized at 100 µg/mL for VRC01, HCA, 
and HSV8. Black bars indicate media pulsed virus, red bars indicate SP pulsed virus. Graph 
representative of n=2. B) Quantification of sperm and virus co-agglutination. Supernatant from 
virus/sperm co-culture treated with different antibodies were quantified with a p24 ELISA. 
  
130 
CD52g+ virus or C) CD52g- virus was used. HSV8 is an isotype control. *p-value< 0.05; **p-value 
<0.0005. Graphs representative of n=3 experiments 
 
HCA offers Modest Protection from HIV-1 in the Presence of Sperm 
HCA trapped both CD52g+ and CD52g- HIV-1 virions in sperm 
agglutinates, decreasing p24 found in sample supernatant. Additionally, HCA on 
its own offered no protection in the TZM-bl neutralization assay. We next tested 
the effect of HCA in HIV-1/sperm co-cultures with an uncoated 
transmitter/founder virus, TRJO (CD52g-) placed in a seminal cell culture 
emulating infected semen. The TZM-bl neutralization assay with the HIV-
1/sperm co-culture reflected the HIV-1/sperm co-agglutination data from Figure 
3-11. Modest protection (measured by percent neutralization) was shown by 
HCA; the highest percentage of neutralization was 23% (Figure 3-12A) in HCA. 
In contrast, HSV8 antibody treatment resulted in a maximum neutralization of 
8% (p-value<0.05). The AUC was calculated as described as in Ghulam-Smith et 
al, (2017)187. VRC01 with high neutralization had an AUC close to 1.0, indicating 
complete protection while HSV8’s AUC was closer to 0.02 showing poor 
protection.  HCA had an intermediate AUC of 0.2  (p-value<0.05; Figure 3-12B). 
  
131 
Therefore, HIV-1 co-agglutination with sperm when treated with HCA decreases 
HIV-1 infection of target TZM-bl cells. 
 
Figure 3-12-Neutralization of TRJO virus in sperm co-culture infection. A) Neutralization curve 
with VRC01 antibody (black), HCA antibody (red), and HSV8 antibody, isotype control (grey). B) 
AUC of each antibody.  Graph is representative of n=2 experiments. C) Neutralization of TRJO 
virus in sperm co-culture infection. In VRC01/HCA antibody concentration, VRC01 is titrated, 
HCA concentration is 50µg/mL. Graph is representative of n=3 experiments ****p-value <0.0001; 
*p-value <0.05 
While HCA does not directly neutralize HIV-1, it does offer modest 
protection in HIV-1/sperm co-agglutinates. We therefore hypothesized that HCA 
could enhance the neutralization of VRC01 at low antibody concentrations. As 
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depicted in Figure 3-12, HCA (at a concentration of 50 µg/mL) rescues some of 
the protection lost at low levels of VRC01. Approximately 50% neutralization 
was found at 1.56 μg/mL of VRC01 when HCA was added, compared to the 29% 
neutralization found with VRC01 alone.  The increased percent neutralization 
could be due to HIV-1 trapping in sperm agglutinates. 
 
Conclusions 
The steady rise of sexually transmitted infections in recent years 
demonstrates the need for an effective microbicide. The problem is exacerbated 
as increased incidence is accompanied by rising rates of antibiotic resistance, the 
discovery of newly identified sexually transmitted pathogens, and unenforceable 
behavioral practices, such as regular screening and condom use. Currently, only 
the condom protects from the sexual transmission of most viruses, bacteria, and 
protozoa; however, its use is often inconsistent6,35,36. While vaccines offer long-
term protection against disease without the use of a physical barrier, the 
complexity of the FRT mucosal immune system has limited product 
advancement: only HepB and HPV vaccine are available to date. Furthermore, 
vaccines can be expensive and need to be administered by medical professionals, 
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limiting access for some populations. Keeping these challenges in mind, an ideal 
microbicide would be easy to use, encourage adherence, and target a wide 
breadth of pathogens. While a long-acting product would be preferable, the 
urgent global need requires that on-demand products be available as well.  
In this study, we investigated HCA’s ability to protect from sexually 
transmitted pathogens, specifically HIV-1 and Trichomonas vaginalis. The GPI 
anchor of CD52g provides the protein with hypermobility. This trait is what 
enables the protein to coat sperm cells after being produced by epithelial cells in 
the MRT. We found that the hypermobility of CD52g also applied to Trichomonas 
vaginalis and HIV-1; both pathogens were coated with CD52g following exposure 
to SP. The subsequent lack of agglutination of CD52g+ TV post-HCA exposure is 
most likely due to the large size of the pathogen: TV is approximately 10 μm long 
and 7 μm in diameter, compared to the 5 μm length and 3 μm diameter of the 
sperm head334–336. Furthermore, the flagella of TV are smaller; and sperm tail-tail 
and head-tail agglutination has been shown with HCA(Figure 2-3). The size of 
TV most likely prevents antibody cross-linking, which is needed for 
agglutination, due to steric hindrance. Additionally, TV are not as motile as 
sperm, leading to fewer collisions which are necessary for agglutination. HIV-1, 
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on the other hand, at approximately 120 nm in size, might be too small to be 
agglutinated, and its movement is limited to Brownian motion. Additionally, 
CD52g does not play a role in the adherence of HIV-1 or its fusion to CD4+ target 
cells, and, unlike VRC01, HCA does not interact with CD4 or CCR5/CXCR4 co-
receptors. As a result, it has no direct role in viral neutralization. 
Our data showed that HCA alone did not have the ability to prevent 
transmission of CD52g-coated pathogens; nevertheless, some protection was 
evidenced when the pathogens were co-cultured with sperm or whole semen 
and treated with HCA. This is likely due to TV and HIV-1 co-agglutinating with 
the sperm. Sperm, therefore, essentially serve as a “net” trapping the pathogens 
in the agglutinates and preventing them from reaching their target cells (Figure 
3-13). This was observed in both the TV/sperm adherence studies, HIV-1/sperm 
co-agglutination studies, and the TZM-bl neutralization assays with HIV-
1/sperm co-cultures. In both cases, there was a decrease in the pathogen’s ability 
to infect (or adhere) to their target cells in the presence of HCA and sperm. 
Hypothetically, the protection offered by the sperm agglutinates trapping 
pathogens or infected cells could be extended to any STI pathogen making HCA 
a modest, but broad-spectrum microbicide.  
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Figure 3-13-Schematic of pathogen-sperm cell co-agglutination in the presence of HCA.  
 
There are limitations in the interpretation of these data and their 
applications in vivo. First, Trichomonas vaginalis studies were performed at 
supraphysiological conditions; the concentration of T. vaginalis in semen likely 
approximates 2500 cells/mL243. Our experimental concentrations were closer to a 
1x106/mL. The increased concentration was used to ensure that a quantifiable 
number of protozoa adhered to tissues and VK2/E6E7 monolayers or were able 
to be visualized by the CASA. As previously mentioned, whole semen, which 
has soluble CD52g, was not used because it completely prevented TV adherence 
to tissue and monolayers. Additionally, some of our methods had limitations. In 
the case of the plate capture method, no dose response was found. My committee 
suggested using beads to remove HIV-1 from the supernatant.  Nonetheless, no 
reduction in p24 concentrations were found. Different buffers, virus 
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concentrations, beads, and antibody concentrations were attempted, and 
troubleshooting is still on-going (data not shown). As previously mentioned, 
TEM data analysis also has to be repeated. While some staining did occur, the 
protocol needs to be optimized. Finally, antibody agglutination and 
neutralization were the sole focus of these studies. The Fc region on antibodies 
enable multiple functions, including opsonization and cellular cytotoxicity which 
are important mechanisms of pathogen protection. Data from recent vaccine 
trials suggest that these non-neutralizing effector functions are responsible for 
eliciting effective immune responses, especially against HIV-1163,164,337. As an IgG 
antibody, it is possible that HCA could elicit these types of responses in the FRT 
that have not been studied in vitro.   
Overall, HCA was not shown to protect target cells and tissues from HIV-
1 or Trichomonas vaginalis infection but, in the presence of sperm cells, it offered 
moderate protection most likely due to co-agglutination in sperm “nets”. As a 
result, HCA could reinforce protection in an antibody-based topical microbicide 
containing pathogen-specific neutralizing antibodies, in addition to offering 
contraception.  
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Chapter 4 - Discussion 
Summary 
This study explores the use of monoclonal antibodies as candidates for 
multipurpose prevention technology, combining both contraceptive and 
microbicidal properties. I started my project by characterizing the activity of the 
anti-HIV antibody VRC01 in genital secretions (Appendix I), but the main focus 
of my dissertation research has been the characterization of another MPT 
candidate antibody, the Human Contraceptive Antibody (HCA). HCA targets 
CD52g, a glycoprotein synthesized exclusively in the male reproductive tract.  
CD52g is GPI anchored, leading to protein hypermobility and enabling CD52g to 
embed in various phospholipid membranes. CD52g embeds in the plasma 
membrane of sperm and seminal leukocytes, and, as demonstrated by this study, 
those of some pathogens such as TV and enveloped viruses like HIV-1 (Figure 
3-3, Figure 3-10).  
HCA is an IgG1 antibody derived from H6-3C4, an agglutinating, anti-
sperm, IgM antibody originally isolated from B cells from an infertile woman by 
Shinzo Isojima283.  His IgM antibody, like our HCA, was known to immobilize 
sperm in the presence of complement. While the specificity and agglutination 
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efficacy of H6-3C4 had been extensively investigated, its production and use for 
the purpose of human contraception had not been previously explored. The 
human IgG1 HCA antibody was produced by transfection of the H6-3C4 DNA 
sequence, with an IgG1 Fc, into modified Nicotiana benthamiana (tobacco) plants 
(Δfucose/Δxylose), a cost-effective antibody production platform.  In this study, 
we demonstrated that the IgG1 isotype of Isojima’s antibody agglutinates sperm 
effectively, despite the decreased valency. We also demonstrated that antibody 
activity and efficacy was not adversely affected by prolonged exposure to low 
pH, such as that found in the human vaginal environment. Additionally, we 
demonstrated that HCA could agglutinate sperm effectively in whole semen—
which contains soluble CD52g—and in the presence of very low or high sperm 
concentrations that represent the physiological range of sperm density found in 
human males. It was necessary to develop new techniques to assess sperm 
agglutination in the presence of HCA for this study.  We developed a kinetic 
sperm agglutination assay that quantified the time elapsed to 100% sperm 
agglutination following treatment with different concentrations of HCA, and the 
“sperm escape assay” which quantified the number of progressive motile sperm 
remaining in a sample five minute after addition of HCA.   Our study, overall, is 
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the first to investigate Nicotiana produced antibodies in the vaginal environment, 
and to characterize the specificity and sperm agglutination activity of the HCA 
mAb (Figure 2-1,Figure 2-2, Figure 2-4). 
We also investigated the ability of HCA to target STI pathogens, a 
function which has not previously been investigated. We determined that 
CD52g, the antigen recognized by HCA, embeds on the phospholipid layers of 
two model STI pathogens, TV and HIV-1 (Figure 3-3, Figure 3-9, Figure 3-10), 
evidencing that CD52g non-specifically associates with pathogens in the male 
reproductive tract, and suggesting that HCA may be active against multiple STI 
pathogens.  The benefit of a ubiquitous target is that a single therapeutic mAb 
could target a variety of bacteria, viruses, and parasites found in semen.  Because 
the non-pathogen specific target, CD52g, is passively acquired, it is unlikely that 
pathogens would develop resistance to HCA. While the CD52g glycoprotein was 
found to embed on the surface of both HIV-1 and TV,  HCA treatment alone did 
not lead to decreased pathogen interaction with target cells or result in inter-
pathogen agglutination (Figure 3-6, Figure 3-11, Figure 3-12).  However, in the 
presence of sperm cells, HCA moderately neutralized HIV-1 in a TZM-bl assay. 
HCA was also found to improve VRC01 neutralization at low concentrations in 
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HIV-1/sperm co-cultures (Figure 3-12). Our data also showed that both seminal 
plasma-exposed (i.e. CD52g-coated) and media-treated TV co-agglutinate with 
sperm after HCA treatment, thus decreasing pathogen adherence to target 
epithelial cells. This HCA co-agglutination “lattice-trapping” effect could reduce 
the infectivity of both CD52g+ and CD52g- pathogens found in semen. 
 
Implications 
HCA was shown to be an effective contraceptive in vitro whose primary 
mechanism of action is sperm agglutination. HCA could function as a short-
acting reversible contraceptive if delivered via intravaginal film, a product 
produced by our industry partner Kentucky BioProcessing (KBP) and currently 
undergoing further testing. However, different delivery methods could be used 
to produce a LARC, such as slow-release intravaginal ring, which the RING and 
ASPIRE studies have shown to be acceptable by patient populations. HCA, 
therefore, is a potential candidate for a novel, non-hormonal, non-barrier 
contraceptive, which would fill an important gap in the contraception field. 
Seminal plasma-exposed pathogens appeared to be trapped in sperm 
lattices upon HCA treatment, in vitro. The trapping mechanism suggests that this 
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potential protection method could be extended to other sexually transmitted 
pathogens not examined in this study, such as Chlamydia trachomatis and 
Treponema pallidum. Additionally, HCA, a primarily contraceptive antibody, 
could be combined with other microbicides, whether they be small molecules or 
biologics, to produce a novel MPT product. As mentioned in Chapter 2, we have 
performed pre-clinical and clinical studies with Nicotiana-produced bnAb 
VRC01-N and HSV8-N. The film containing both of these antibodies is MB66. 
The first segment of the Phase I clinical trial of MB66 tested the safety of the 
intravaginally applied mAb film and determined ex vivo function of the antibody 
after 24 hours in the vaginal tract. The clinical trial data reflected the results of 
our pre-clinical in vitro studies where VRC01-N was incubated with 
cervicovaginal lavage (CVLs) or seminal plasma (SP) samples and demonstrated 
no loss of neutralization efficacy against both Q23-17 and BAL (R5 tropic) viral 
strains (Appendix 1A-B). VRC01-N/MB66 also demonstrated no significant loss 
of efficacy when exposed to lactic acid, pH 3.9, for up to 8 hours, and showed 
only a mild decrease in activity after 24 hours (Appendix 1C-E). The first 
segment of this clinical study included a PK study in which VRCO1 
concentrations were assessed in TearFlow and CVL samples at time points up to 
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24 hours post-film insertion.  Antibodies were readily detected in TearFlo and 
CVL samples for up to 24 hours, but levels returned to baseline after 6-7 days. 
Segment B recently concluded. The second segment tested film safety with more 
trial participants and repeat film applications. Participants were requested to 
administer a film every day for 7 days. Elevated levels of VRC01-N and HSV8-N 
were found in TearFlo and CVL samples for 24 hours after the last film was 
applied. Additional studies with macaques have provided promising data for 
antibody administration using an intravaginal ring. Macaques with slow-
releasing pods containing VRC01-N antibody had rings inserted in the posterior 
vagina, and VRC01-N was detected with TearFlow strips for up to 21 days338. 
Overall, the data presented here provides evidence for an antibody-based MPT 
product containing HCA and VRC01-N antibodies produced in Nicotiana plants. 
The use of Nicotiana as an antibody producing platform is important for 
MPT development because it enables this product to be affordable and 
accessible. As mentioned previously, antibodies in Nicotiana can be quickly 
produced (40 days) in large quantities resulting in decreased manufacturing 
costs. This means that mAb MPTs could be available globally even for 
populations with limited resources. Storage of the antibody in film form has been 
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shown in our lab to preserve HCA stability and function at 4 °C which suggests 
flexibility in storage conditions. Antibody stability in film at RT remains to be 
tested. If room temperature stability can be demonstrated and low-cost 
production can be achieved, this film could become a much needed, antibody-
based MPT—a valuable product that could curb the rise of STIs while providing 
the option of contraception, with HCA.  
 
Study Evaluation: Strengths and Limitations 
We are grateful to the semen donors who participated in this study. 
Working with a steady reserve of human samples has simultaneously been one 
of the greatest strengths and challenges of this study. During the course of the 
study, we used approximately 20 donors. The variability of our samples was 
evident in both sperm count (~13 M/mL-180 M/mL) and mobility (<20%-80%), 
presence or absence of round cells, and sample volume (1 mL-7 mL). Donor-to-
donor variability in seminal fluid, such as in the case of cytokine concentrations, 
has been well documented. In order to minimize any effect a single donor may 
have on the outcome of an experiment, 2-3 donors were pooled if whole semen 
was used. Our large pool of donors allowed for different combinations of 
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samples, generally, to be pooled for each experiment. While pooling controlled 
for variability in general, there were unique challenges of working with whole 
semen. Semen and seminal plasma can be cytotoxic to cells in vitro. Trichomonas 
vaginalis, PBMCs, T cell lines, and epithelial cells were able to withstand brief 
exposures to SP. HEK293T cells survived the treatment but became non-adherent 
and had to be re-plated after the SP was removed. The effect of SP on TZM-bl 
cells was inconsistent; the cells sometimes survived SP exposure, but other times, 
lifted off the plate and apoptosed in under two hours. Interestingly, sperm had 
variable viability in whole semen as well, with motility being conserved best if 
sperm were isolated and resuspended in MHM. Our lab has demonstrated that a 
1/32 dilution of SP allowed for overnight incubation of TZM-bl cells without 
decreasing viability; however, this diluted the sperm to sub-physiological 
concentrations. Difficulty preserving viability clearly limited our HIV-1/sperm 
TZM-bl neutralization studies since whole semen, which would be more 
physiologically relevant, could not be used. In the case of TV adherence studies, 
semen/seminal plasma prevented the adherence of the protozoa to epithelial 
cells, a situation circumvented by the pathogens in vivo. Removing SP from 
sperm cells was necessary to obtain results. It is important to note that semen, 
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FRT secretions, and the interaction between the two, may have additional 
protective and/or permissive functions in vivo which could not be observed in 
our in vitro experiments. Animal models could theoretically shed light on these 
interactions, but there are limitations for all available models. In our case, the 
presence of CD52g in the MRT is only observed in higher primates (great apes, 
humans). Furthermore, the human vagina has a unique structure and low pH 
that is not found in any other animal, limiting the conclusions that can be 
derived from these studies, and favoring in vitro work.  
Despite the limitations of working with whole semen, we attempted to 
maintain physiologically relevant conditions to the best of our ability, such as in 
the case of our pathogens. NL43 virus (R4 tropic) was used initially as a learning 
tool due to its GFP tag that allowed for infection monitoring during protocol 
troubleshooting. However, HIV-1 is sexually transmitted by R5 tropic virus 
produced by infected CD4+ cells. For later studies, TRJO virus was used. TRJO is 
a Clade B, R5 tropic, transmitter-founder virus. It was selected because of the 
early Fiebig stage (II) of the male patient from which the virus was isolated339. It 
is also known to infect macrophages, which are potential disseminators of 
infection in the FRT. There are also limitations with this virus selection. The virus 
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is Clade B which is predominant in the USA and Western Europe but represents 
only 12% of HIV-1 infections worldwide. Clade C is the most prevalent clade 
worldwide, and is found predominantly in southern Africa and India182. 
Limitations also existed when working with Trichomonas vaginalis. The B7RC2 
strain is well-documented WT TV strain and known to adhere to epithelial cells 
in vitro within an hour340,341. Trichomonas vaginalis, however, is an obligate 
anaerobe; VK2/E6E7 cells and MatTek tissues are obligate aerobes. As is the case 
with most FRT research, the combination of anaerobic and aerobic organism is a 
challenge for long-term assays. In vivo, the lumen of the vaginal tract is known to 
be a microaerophilic environment permitting the growth of both aerobic and 
anaerobic organisms. The aerobic vaginal tissue is maintained by the circulatory 
system. In an in vitro setting, it is difficult to combine the two conditions. We 
circumvented this difficulty by keeping TV adherence to an hour, a time 
constraint that preserved TV viability. Adherence was also encouraged by 
sealing MatTek and VK2 cultured plates with parafilm to avoid oxygen exchange 
in the absence of an anaerobic chamber. These efforts were intended to allow 
experimental conditions to mimic physiologically relevant conditions as closely 
as possible in a laboratory setting. Nevertheless, as evidenced by Figure 3-6, this 
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set-up was not sufficient to improve SP-pulsed Trichomonas vaginalis adherence 
which is decreased compared to media controls. SP also interfered with 
protozoal adherence, and it is possible that the decreased adherence was not due 
to the condition of TV post-exposure to SP, but to components of SP itself that 
remained in the sample despite washing. 
One of the greatest strengths of using Nicotiana-based antibodies is 
reflected by the Luminex panel and the MB66 clinical trial: the safety profile of 
the product is promising. There was no significant increase of pro-inflammatory 
cytokines by vaginal epithelial cells in vitro and only one mild adverse event 
related to the product documented in the Phase I, segment A clinical trial of 
MB66317. The balance between safety and efficacy has historically been delicate, 
as evident in the case of nonoxynol-9 (N-9), a commercially available spermicide. 
N-9 is a surfactant which kills sperm effectively, preventing unplanned 
conception when used correctly. However, it was also shown to negatively affect 
vaginal epithelial cell integrity and compromise the barrier’s protection against 
STIs with no microbicide effect49. Overall, our in vitro and pre-clinical studies 
indicate that an antibody-based MPT could work in tandem with the FRT 
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immune response, and could potentially be used in conjunction with other 
contraceptive or microbicidal compounds for enhanced efficacy.  
 
Future directions 
 
A large portion of this work was dedicated to developing in vitro assays that 
assessed mAb contraceptive and microbicidal efficacy in physiologically relevant 
conditions. The scope of this study was therefore limited to the agglutination and 
pathogen-neutralization functions of HCA. Antibodies can have other effector 
functions which could also play a role it the contraceptive/microbicidal effects of 
HCA:  
1. Opsonization and phagocytosis (ADCP)- where antibody coats the 
pathogen, enabling macrophages and neutrophils to efficiently 
phagocytose the antibody target; 
2. Complement fixation- where complement interacts with antibodies 
bound to their epitope and can result in the formation of the membrane 
attack complex (MAC) which leads to cell death. Complement in the 
human FRT has been poorly studied and the magnitude of the protection 
it offers remains to be understood.  
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3. Cell mediated cytotoxicity (ADCC)- where antibody bound to an infected 
cell leads to NK cell- induced apoptosis of the target.  
HCA, as an IgG1 antibody, has the potential to induce any of these functions 
in the FRT. Their relevance and potential to enhance the contraceptive and 
microbicidal properties of HCA remains to be explored. Similarly, and of great 
concern since CD52g coats the envelope of HIV-1 without neutralizing it, is the 
possibility that antibody dependent enhancement of infection. This potential 
adverse effect of HCA remains to be determined.  
The function and efficacy of HCA in vitro has been determined in this 
study, but improvements can continue to be made via an improved delivery 
system or continued antibody engineering. Our current Nicotiana-produced 
antibodies, VRC01-N and HSV8-N, have been incorporated into a film that is 
manually inserted into the vagina. The film dissolves quickly in the vagina and 
the released antibody is found in high concentrations for up to 24 hours after a 
single application without losing neutralization potency. The current form of the 
potential MPT makes it a short acting, on-demand product. However, 
incorporation of mAbs into an intravaginal ring with controlled antibody release 
could convert the MPT into a long-acting product, if adequate antibody levels 
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can be maintained in the tissue. Promising IVR mAb pharmacokinetics research 
is already underway in the laboratory of Francois Villinger in the Rhesus 
macaque model. Furthermore, the possibility of a long acting (3+ month) IVR 
MPT is being explored by the International Partnership for Microbicides (IPM) 
where levonorgestrel was added to the Dapivirine ring explored in The 
Ring/ASPIRE studies. Phase I clinical trials are currently underway73.   
Finally, current technology enables antibodies to be engineered in novel, 
ingenious ways that improve antibody function. Our collaborator, MappBio, 
recently made an HCA-hexamer (Hex) mAb which contains 5 F(ab’)2 components 
(Appendix 2, Panel A). Preliminary data indicate that the Hex antibody is a more 
potent agglutinator of sperm (and possibly pathogens) through increased 
valency. The engineered Hex antibody significantly outperformed HCA IgG1 at 
lower concentrations in the agglutination kinetics (Appendix 2, Panel B), and 
sperm escape assays (Appendix 2, Panel C). The data suggest that the novel Hex 
antibody could decrease the amount of antibody needed to achieve levels of 
protection, perhaps decreasing product costs. Furthermore, the data provide 
evidence that increased valency leads to faster, more robust agglutination, which 
can also be explored with an IgM isotype of HCA. The safety profile of Hex-like 
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antibodies remains to be determined; IL-6 was noticeably increased in MatTek 
tissue after Hex antibody treatment, although no other inflammatory cytokines 
were increased. 
 
Conclusion 
HCA is a powerful sperm agglutinator that performs consistently across 
donors, and is not significantly impacted by prolonged exposure to the low pH 
of the vagina. Its microbicidal properties, nonetheless, are mostly limited to 
pathogen trapping in sperm agglutinates. HCA, however, can potentially work 
in combination with other Nicotiana-produced antibodies, such as VRC01-N, to 
constitute a topical antibody-based MPT.  The resulting MPT could have the 
potential to fulfill a much needed gap in women’s health: a readily accessible, 
low-cost, non-hormonal, non-barrier contraceptive and microbicide MPT that is 
reversible and discreet. 
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APPENDIX 1: VRC01 and MB66 neutralization in the presence of 
genital secretions and lactic acid 
 
 
Figure A1.1- Effect of  genital secretions on neutralization of HIV-1 by MB66. A modified 
TZM-bl neutralizing antibody assay was used to evaluate VRC01-N and MB66 neutralization 
after incubation with CVLs or SP with A) Q23-17 HIV-1 virus and B) BAL HIV-1 virus strain. 
Graphs are representative of three experiments. C) A modified TZM-bl neutralization assay was 
used to evaluate VRC01-N and MB66 efficacy after 1% LA exposure for 2 hours, D) 4 hours, and 
E) 24 hours. Graph is representative of two experiments. 
For panels A and B, VRC01 and MB66 were diluted in either TZM-bl 
media, CVL samples, or SP samples generously provided by the Integrated 
Clinical/Pre-clinical program for HIV topical microbicides (IPCP-HTM) and 
approved by Boston University’s IRB. Antibody and film were diluted in genital 
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secretions before being added to virus for 30 minutes and following the TZM-bl 
neutralization protocol as described in Chapter 3. Antibodies were tested using 
both Q23-17 (panel A), considered a transmitter-founder virus, and BAL virus, a 
lab adapted R5 virus (Panel B). As shown by the graphs, 100% neutralization was 
found for 1 µg/mL of VRC01 with both BAL and Q23-17 virus. CVL-treated 
antibody at low concentrations had the lowest percent inhibition at 0.1 µg/mL 
when using BAL virus, and SP-treated antibodies had the lowest percent 
inhibition at 0.1 µg/mL when using Q23-17. To examine the effect of LA on 
VRC01 neutralization ability, the antibody was previously incubated with 1% LA 
for 2, 4, and 24 hours. The antibody solutions were neutralized (pH 7) with 1N 
NaOH before carrying out the TZM-bl neutralization assay as described in 
Chapter 3. As shown in panels C-E, neutralization efficacy is mildly decreased 
after 24 hours at low pH. The LA treated placebo film also shows neutralization 
at the highest concentration. This was expected as LA has been shown to protect 
from HIV-1 infection241.  
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APPENDIX 2: Preliminary studies with Hex antibody 
 
 
Figure A2.1- Agglutination assays with engineered, multivalent CD52g specific antibody. 
MappBio produced a multivalent antibody with a predominantly IgG1 Fc joined by an IgM tail. 
Diagram courtesy of Ellena Nador. B) Kinetic agglutination assay comparing HCA (black) with 
the hexamer (red). C) Sperm escape assay with Hex and HCA. Graphs representative of two 
experiments. D) Luminex panel of MatTek tissue apical (left panel) and basal (right panel) 
supernatants. IgG/M tail= Hex antibody. Graph representative of one experiment. 
 
Mappbio Pharmaceuticals, our collaborators, manufactured a multivalent CD52g 
specific antibody. The antibody joined six IgG antibodies with an IgM tail to 
form a hexamer (Hex). We compared our monomer HCA to the multivalent 
antibody at low concentrations using the kinetic assay (panel B) and the sperm 
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escape assay (panel C) as described in Chapter 2. The low antibody 
concentrations were used to better detect the differences between antibody 
efficacy. HCA performed comparably to the multimer at concentrations ≥6.25 
µg/mL. At lower concentrations, Hex agglutinated up to three-fold faster than 
HCA. The sperm escape assay also provided evidence that the Hex antibody 
agglutinated progressive sperm more consistently and efficiently than HCA at 
lower concentrations. MatTek tissue was used for preliminarily assessment of 
safety by quantifying cytokine production upon epithelial exposure to both 
soluble HCA and Hex (here denoted IgG/M). As shown in panel D. There is a 2-
3-fold increase in IL-6 production detected in both the apical and basal 
supernatants which was not found in HCA. Further studies must be done to 
ensure pre-clinical safety with this novel antibody.  
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